

## 37<sup>TH</sup> EUROPEAN IMMUNOGENETICS & HISTOCOMPATIBILITY CONFERENCE

MAY 20–23, 2024 GENEVA SWITZERLAND

Unveiling Diversity, Nurturing Transplant Bonds, Orchestrating immunity



Î

# FINAL PROGRAM





## CONTENT

WELCOME ADDRESS	3
SPONSORS AND EXHIBITORS	4
CONFERENCE INFORMATION	6
REGISTRATION	9
INSTRUCTIONS FOR SPEAKERS (ORAL)	11
INSTRUCTIONS FOR POSTER PRESENTERS	12
ORGANISERS AND COMMITTEES	13
SPEAKERS	14
PROGRAM AT GLANCE	16
DETAILED PROGRAM	18
LIST OF POSTERS	26
SATELLITE SYMPOSIA	48
PARTNERS	50
SOCIAL NETWORKING EVENTS	53







## **WELCOME ADDRESS**

### Dear scientists, Dear EFI members,

It is with great pleasure and excitement that we welcome each one of you to the 37<sup>th</sup> Conference of the European Federation for Immunogenetics (EFI) in Geneva.

As we come together for this significant gathering, it is a testament to our shared commitment to advancing the field of Immunogenetics. Over the four days of the conference, we will have the privilege of engaging with cutting-edge research, insightful discussions, and networking opportunities. The scientific program is designed to cover a spectrum of topics, from the latest technological advancements to the ethical considerations that underscore our work in Immunogenetics. Our distinguished lineup of speakers, experts, and panelists will share their expertise, providing invaluable insights that will inspire and challenge our thinking.

Don't miss the final state-of-the-art lecture to navigate through our universe and beyond by learning more on exoplanets, a big field of expertise at the University of Geneva.

A conference of this size is not possible to arrange without the support from a number of faithful sponsors, who have prepared very interesting symposia. We sincerely thank all of them for their financial and scientific contributions.

We also hope that you will take time to visit and enjoy the international and peaceful atmosphere of Geneva, the smallest of the biggest capitals, which hosts international organisations, such as the European headquarters of the UN, the Red Cross, the WHO and a dozen of non-governmental organisations.

Hereby, we would like to express our gratitude to the EFI Executive Committee, the EFI Scientific Committee, the EFI Education Committee, to the members of the Organizing Committee as well as our PCO. They have all provided us with invaluable help and support in preparing the scientific program, organizing teaching sessions, evaluating abstracts and preparing the Conference.

### Thank you for being an integral part of EFI 2024 in Geneva.

### Here's to an inspiring and transformative conference!

From the local organizing committee **Sylvie Ferrari-Lacraz and Jean Villard** 







## **SPONSORS AND EXHIBITORS**

WE WOULD LIKE TO THANK THE FOLLOWING PARTNERS FOR THEIR SUPPORT

**Platinum Partners** 









**Silver Partners** 







**Bronze Partners** 







## HISTOGENETICS



Special thanks to



The water bottles partner

The lanyards partner

HISTOGENETICS

The fondue forks partner



**Tulip Run partner** 







**Exhibitors** 







**Supporters** 





5




## **CONFERENCE INFORMATION**

### **CONFERENCE VENUE**


Palexpo Geneva www.palexpo.ch

**First floor** 






## **Ground floor**







### **EXHIBITION PLAN**



### List of Exhibitors

- 1 GenDx
- 2 CareDx, Inc.
- **3** Thermo Fisher Scientific
- 5 Werfen
- 6 DiagnoSeq
- 7 Hansa Biopharma
- 8 Devyser
- 9 Omixon
- 10 DKMS Life Science Lab gGmbH

### FREE WI-FI

SSID: EFI2024 Password: Geneva2024

### **EFI 2024 MOBILE APPLICATION**

With the mobile application, you will have access to the detailed program and all the important information related to the conference.

Download the mobile app in the App Store / Google Play.



### EFI SOCIAL MEDIA

Follow EFI on Social Media

f https://www.facebook.com/EFI2024

https://twitter.com/i/flow/login?redirect\_after\_login=%2FConferenceEfi

https://www.linkedin.com/company/efi-conference-2024/

As for EFI conference 2024 use #EFI2024.

- **11** BAG Diagnostics GmbH
- **12** HistoGenetics
- **13** Pirche AG
- 14 Protrans medizinische diagnostische Produkte GmbH
- 15 EFI Office
- 16 inno-train Diagnostik GmbH
- 17 JETA Molecular
- **18** STEMCELL Technologies





## REGISTRATION

### SELF-CHECK-IN

On-site registration and issue of badges will take place at self-check-in stations. You will receive a QR code before the conference via email. You can print the QR code or use your mobile device to obtain your badge.

### **On-site Registration Fee**

Member	760 EUR
Non-member	860 EUR
Technician	490 EUR
Student	490 EUR
Retired	490 EUR
One-day fee (May 21/22)	530 EUR
One-day fee (May 23)	430 EUR
Distributor	270 EUR
Accompanying Person	160 EUR

Registration fee includes 8,1% VAT.

### The Registration Fee Includes:

- Access to the conference and all its sessions (not included for Accompanying Persons)
- Welcome Cocktail
- Opening ceremony
- Coffee and lunch breaks
- Wine and cheese poster session

The distributor fee allows for access to the exhibition only. Access to the sessions need a full conference ticket.

### The One-day Registration Fee Includes:

- Access to the conference and all sessions taking place on the selected day
- Coffee and lunch breaks

### The Accompanying person's Registration Fee includes:

- Access to the building and exhibition
- Welcome Cocktail
- Wine and cheese poster session
- Accompanying persons do not have access to scientific sessions

### **REGISTRATION DESK**

#### **Opening Hours**

Monday, May 20, 2024	08:00–20:00
Tuesday, May 21, 2024	07:30–18:30
Wednesday, May 22, 2024	08:00–18:30
Thursday, May 23, 2024	08:00-14:00





### NAME BADGE

All delegates will receive a name badge upon registration. Everyone is kindly requested to wear his/her badge when attending the conference.

DELEGATE		
SPEAKER		
ONE-DAY FEE (MAY 21,22)		
ONE-DAY FEE (MAY 23)		
ORGANIZER		
PARTNER / EXHIBITOR		
ACCOMPANYING PERSON		

### **CERTIFICATE OF ATTENDANCE**

All delegates will receive a certificate of attendance after the conference by email.







## **INSTRUCTIONS FOR SPEAKERS (ORAL)**

Please prepare your presentation in 16:9 format (screen is in format ratio 16:9).

We recommend to save your PowerPoint presentation using PPT(X) format.

Each presenter will be given a time slot of 10 minutes in total. Each oral presentation should not exceed 8 minutes. It will be followed by 2 minutes discussion.

All speakers are requested to strictly keep their allocated time slots. Session chairs will enforce the schedule.

### SPEAKERS' READY ROOM

All session halls are equipped with standard PowerPoint presentation facilities.

All presentations will be networked to the appropriate room "Speakers' Ready Room" (Office 6, located on the first floor of the venue).

All speakers are asked to submit their presentations to the Speakers' Ready Room at least 1 hour prior to the session you present in.

#### Early morning presentation:

Please submit your presentation the day before.

We kindly ask you to hand in your presentation to the technical staff in the Speakers' Ready Room on-site via an external drive. While doing so, we encourage speakers to verify their presentation. This will ensure no formatting errors.

IT support will be available in all the conference rooms during live sessions. All speakers are kindly requested to use provided PC onsite.

Please be present in the session room 15 minutes before the start of your session and follow the instructions from the Chairs and/or technician.

During your presentation, a remote control will be available for controlling your presentation. Please observe the time allotted to you as you will not be permitted to speak for a longer time.

At the end of the conference, all presentations will be deleted from the presentation system and computers on-site.

### **Opening hours of the Speakers' Ready Room**

Monday, May 20, 2024	15:30-20:00
Tuesday, May 21, 2024	07:30-18:00
Wednesday, May 22, 2024	08:00-18:30
Thursday, May 23, 2024	07:30–12:30





## **INSTRUCTIONS FOR POSTER PRESENTERS**

The poster section is located in the foyer of the 1<sup>st</sup> floor and in the Alpha + Beta rooms.

All posters will be presented in a "paper" format (printed posters) and will be organized according to the paper ID numbers.

- Posters must be prepared in PORTRAIT style (please DO NOT prepare a landscape poster). The recommended dimensions (for a good legibility) are 84.1 × 118.9 cm wide. (format A0). Do NOT exceed the overall dimensions of the poster board (180 cm high by 95 cm wide).
- Posters will be displayed throughout the whole conference.
- Posters should be attached to the boards (smooth surface) with stickers, which will be supplied by the organisers.
- Fixing material (adhesive gum, standard tape) will be available in the Posters Area
- The poster boards will be numbered by the organizers.

The number of your poster can be found in the <u>List of posters</u>. The presentation number assigned to your poster should not be placed on your poster.

### **POSTER CREATION**

The header of the Conference can be downloaded here (JPG format, PDF format), and the instructions on layout, font style, and margins are in the attached preview. The preview is informative only. The text, illustrations, etc. should be big enough to be read from a distance of 1.5 meters, and the message of the poster should be clear and understandable.

Please print your poster and bring it with you to the Conference. **No** poster printing service is provided by the organizers. Please **DO NOT** prepare a landscape poster.

### A SPECIAL SESSION

### Poster Session viewing is scheduled on Tuesday, May 21 from 18:00-20:00

Be at your poster during this poster session to discuss your work with scientists visiting your poster. A Selection of posters will be assessed for best posters awards. The best posters awards will be announced during the closing ceremony on Thursday, May 23, from 12:00.

Poster mounting time:		
Monday, May 20, 2024	16:00–19:30	
Tuesday, May 21, 2024	07:30–10:00	

**Poster removal time:** 

We ask the presenters to remove their posters during the removal time, otherwise they will be removed and discarded by the organizer.





## **ORGANISERS AND COMMITTEES**

### LOCAL ORGANIZING COMMITTEE

Jean Villard, Chair, Switzerland Sylvie Ferrari-Lacraz, Switzerland Stéphane Buhler, Switzerland Valérie Olivier, Switzerland José Manuel Nunes, Switzerland Alicia Sanchez-Mazas, Switzerland

### EFI SCIENTIFIC COMMITTEE AND ABSTRACT REVIEWERS

Luca Vago, Chair, Italy Lotte Wieten, the Netherlands John Trowsdale, United Kingdom Alicia Sanchez-Mazas, Switzerland Raphael Carapito, France Pietro Crivello, Germany Katharina Fleischhauer, Germany

### **EFI EXECUTIVE COMMITTEE**

Ann-Margaret Little, President, United Kingdom Marco Andreani, President-elect, Italy Dave Roelen, Secretary, the Netherlands Kay Poulton, Deputy Secretary, United Kingdom Jean Villard, Treasurer, Switzerland Nicolas Vince, Deputy Treasurer, France Sebastiaan Heidt, Councilor, the Netherlands Falko Heinemann, Councilor, Germany Neema Mayor, Councilor, United Kingdom Antonij Slavcev, Councilor, Czech Republic David Turner, Councilor, United Kingdom Luca Vago, Councilor, Italy





## CS)

## **SPEAKERS**

Plenary 1: Solid Organ Transplantation (How to Transplant Highly Sensitized Patients) Lori West, Alberta Transplant Institute, Canada Mats Bengtsson, Uppsala University Hospital, Sweden Pernille Bundgaard Koefoed-Nielsen, Aarhus University Hospital Denmark

### Plenary 2: Hematopoietic stem cell transplantation (New therapies for acute leukemia: HSCT, CAR-T, Bispec-Ab) Jakob Passweg, USB, Basel Catherine Thieblemont, APHP, Saint Louis

Federico Simonetta, HUG, Geneva

Plenary 3: HLA Immunogenetics and Population Genetics a combined SIP-EFI session Alicia Sanchez-Mazas, UNIGE Diogo Meyer, Sao Paulo, Brazil Paul Norman, CU Anschutz, Denver, Colorado

Plenary 4: Giving life-bone marrow / solid organ donors Johannes Schetelig, Dresden UniversityKlinik and DKMS Constanca Figueiredo, Medizine Ochshule Hannover Efstratios (Stratos) Chatzixiros, World Health Organization (Switzerland)

### Plenary 5: Antigen presentation and neoantigens Giacomo Oliveira, Harvard, Boston Andrea Sotto, Human Technopole, Milan

Andrea Sotto, Human Technopole, Millan Michal Bassani-Steinberg, CHUV

### SFHI session

Thomas Fehr, Kantonspital Chur Fadi Issa, Oxford, UK Tifanie Blein, Institut Imagine, Paris

## Network immune cell session

Mikaël Pittet, UNIGE Camilla Jandus, UNIGE David Gfeller, UNIL

### **DP special session**

Katharina Fleischhauer, Essen, Germany Julien Racle, UNIL Effie Petersdorf, Fredhutchinson, Seattle Stéphane Buhler, HUG, Geneva, Switzerland

### **Teaching KIR**

Paul Norman, CU Anschutz, Denver, Colorado Alice Koenig, CHU Lyon, France Stéphane Buhler, HUG, Geneva, Switzerland

### **Teaching transfusion**

Deborah Sage, NHS, London, UK Anthony Poles, NHS, Bristol, UK Agnes Basire, EFS, Marseille


### Teaching HLA and disease

**Gwendaline Guidicelli,** CHU Bordeau, France **Frantisek Mrazek,** Olomuc University Hospital, Czech Republic **Deborah Pritchard,** Wales, UK



Young professionals session Sandra Tafulo, Portuguese Institute for Blood and Transplantation, Porto, Portugal Nicolas Vince, Nantes University, France Lovis Christian, HUG, Switzerland

Closing ceremony Monika Lendl, UNIGE







## **PROGRAM AT GLANCE**

TIME	MONDAY, MAY 20, 2024
	Hall B
07:30	Registration
17:30	17:30-19:15 Opening Ceremony

TIME	TUESDAY, MAY 21, 2024			
	Hall A	Hall B	Hall C	Hall K
07:30	Registration			
08:30		08:30–10:00 Plenary session I Solid Organ Transplantation (How to Transplant Highly Sensitized Patients)		
10:00		Coffee	Break	
10:30	10:30–12:00 Abstract session 1 Immunotherapy, gene therapy & NK cells	<b>10:30–12:00</b> Special joint SFHI session – Tolerance	10:30–12:00 Abstract session 2 Bioinformatics, data analysis in immunogenetics	<b>10:30–12:00</b> <b>Teaching session 1</b> HLA and transfusion
12:00	Lunch			
12:10	12:10–12:50 Industry symposium Werfen			
13:10		13:10–13:50 Industry symposium CareDx		
14:00	14:00–15:30 Abstract session 3 New technologies in Immunogenetics	<b>14:00–15:30</b> Special joint session with the Geneva University – The network of immune cells in health and disease	14:00–15:30 Abstract session 4 Immunogenetics in organ transplantation 1	<b>14:00–15:30</b> <b>Teaching session 2</b> HLA and diseas
15:30		Coffee	Break	
16:00		<b>16:00–17:30</b> <b>Plenary session II</b> Hematopoietic stem cell transplantation (New therapies for acute leukemia: HSCT, CAR-T, Bispec-Ab)		
17:30	<b>17:30–18:10</b> Industry symposium Omixon	<b>17:30–18:00</b> Serological nomenclature: update	<b>17:30–18:10</b> Industry symposium Hansa Biopharma	
18:10	Wine and Cheese I		<b>-20:00</b> ster area on the 1 <sup>st</sup> Floor & A	lpha + Beta rooms





TIME	WEDNESDAY, MAY 22, 2024			
	Hall A	Hall B	Hall C	Hall K
08:00		Regist	tration	
08:30		08:30–10:00 Plenary session III HLA Immunogenetics and Population Genetics a combined SIP-EFI session		
10:00		Coffee	Break	
10:30	<b>10:30–12:00</b> <b>Abstract session 5</b> Immunogenetics in organ transplantation 2	<b>10:30–12:00</b> Special session – HLA DP models and beyond	<b>10:30–12:00</b> <b>Abstract session 6</b> MHC evolution, population genetics	
12:00		Lu	nch	
12:10	<b>12:10–12:50</b> Industry symposium Thermo Fisher Scientific			
13:10	13:10–13:50 Industry symposium GenDx			
14:00	14:00–15:30 Abstract session 7 Hematopoietic stemcell transplantation	<b>14:00–15:30</b> Young EFI professional special session – Al and big data in immunogenetics	14:00–15:30 Abstract session 8 Autoimmunity, Infection, Reproduction & Cancer	14:00–15:30 Teaching session 3 KIR in solid organ and hematopoietic stem cell transplantation
15:30	Coffee Break			
16:00		<b>16:00–17:30</b> <b>Plenary session IV</b> Giving life- bone marrow / solid organ donor		
17:30		<b>17:30–18:00</b> EFI Medals Ceremony		
18:00		<b>18:00–19:00</b> EFI General Assembly		

TIME	THURSDAY, MAY 23, 2024		
	Hall B		
07:30	Registration		
08:30	08:30–10:00 Best abstract session		
10:00	Coffee break		
10:30	10:30–12:00 Plenary session V Antigen presentation and neoantigens		
12:00	12:00–13:00 Closing Ceremony		



## **DETAILED PROGRAM**

## **ASSOCIATED MEETINGS**

## SUNDAY, MAY 19, 2024

## Room $\alpha$ + $\beta$ (Alpha + Beta)

09:00–17:00Inspectors workshopChairpersonsBlanka Vidan-Jeras, Christien Voorter, Sabine Scherer

## Rooms I (lota), $\omega$ (Omega), Office 5, Office 6

09:00–17:00 ESHI diploma examination

## MONDAY, MAY 20, 2024

Rooms θ (Theta), ω (Omega), ι (lota), σ (Sigma), ζ (Zeta), ε (Epsilon), η (Eta)			
08:30-16:30	Executive committee meeting	θ (Theta)	
	External proficiency testing committee meeting	ω (Omega)	
	IT & bioinformatics committee meeting	ı (lota)	
	Accreditation committee meeting	σ (Sigma)	
	Standards committee meeting	ζ (Zeta)	
	Education committee meeting	ε (Epsilon)	
	Scientific committee meeting	η (Eta)	
Chairpersons	Chairs of each committee		



## **SCIENTIFIC PROGRAM**

## MONDAY, MAY 20, 2024

12:00–13:30	Population Genetics Working Group (Open Meeting)	
Chairpersons	A. Sanchez-Mazas, José Nunes	
Hall B		
17:30–19:15	Opening Ceremony	
17:30–18:00	<b>Welcome addresses</b> EFI President, Dean of the Faculty, Health Minister	
18:00–18:15	HLA award Steven Marsh	
18:15–18:45	Julia Bodmer award Luca Vago	
18:45–19:15	Ceppellini lecture Ann-Margaret Little	

**Exhibition Hall** 

19:30–21:30 Welcome reception





## **TUESDAY, MAY 21, 2024**

Hall B	
08:30-10:00	Plenary session I
	Solid Organ Transplantation (How to transplant highly sensitized patients)
Chairpersons	Valérie Dubois, Sebastiaan Heidt
08:30–09:00	New approach to ABO – Incompatible transplantation Lori West
09:00–09:30	Is Imlifidase the new magic bullet for highly sensitized recipients? Mats Bengtsson
09:30-10:00	<b>10 years of the Scandiatransplant acceptable mismatch program</b> Pernille Bundgaard Koefoed-Nielsen

## PARALLEL SESSIONS

Hall B		
10:30-12:00	Special joint SFHI session Tolerance	
Chairpersons	Paul Rouzaire, Alice Aarnink	
10:30-11:00	Mixed chimerism for induction of renal allograft tolerance Thomas Fehr	
11:00–11:30	Development and assessment of T cell therapies for transplantation Fadi Issa	
11:30–12:00	Genetic engineering to empower Treg therapy Tifanie Blein	
Room K		
10:30-12:00	Teaching session 1 HLA and transfusion	
Chairpersons	Deborah Sage, Agnès Basire	
10:30-11:00	Human platelet antigens - Definition and laboratory investigation Anthony Poles	
11:00–11:30	Fetal and neonatal alloimmune thrombocytopenia diagnosis and management: a commissioner point of view Agnes Basire	
11:30–12:00	Platelet refractoriness: laboratory diagnosis and patient management Deborah Sage	
Hall A		
10:30-12:00	Abstract session 1: Immunotherapy, gene therapy & NK cells	

Chairpersons Britta Eiz-Vesper, Roberto Crocchiolo

### Hall C

10:30–12:00Abstract session 2: Bioinformatics, data analysis in immunogeneticsChairpersonsMartin Maiers, James Robinson





Room θ (Theta	)
12:00-13:00	EC + ECC meeting
Hall A	
12:10-12:50	Industry symposium: Werfen
Hall B	
Hall B 13:10–13:50	Industry symposium: CareDx
13.10-13.50	
Room $\sigma$ (Sigm	a)
13:30-14:30	CME/CPD Launch meeting
PARALLEL SES	SIONS
Hall B	
14:00-15:30	Special joint session with the Geneva University
Chairpersons	The network of immune cells in health and disease Nicole Mifsud, Frans Claas
14:00–14:30	The neutrophil and macrophage networks Mikaël Pittet
14:30-15:00	The ILC network
15:00–15:30	Camilla Jandus The T/TCR network
	David Gfeller
Room K	
14:00-15:30	Teaching session 2
	HLA and disease
Chairpersons	Gwendaline Guidicelli, Deborah Pritchard
14:00-14:30	Best practices for HLA and Genetic Testing in H&I laboratories: SFHI Guidelines
14:30–15:00	Gwendaline Guidicelli <b>Current position of disease associations with the HLA system in clinical diagnostics</b>
45.00 45.00	Frantisek Mrazek
15:00–15:30	HLA genetics and Coeliac disease Deborah Pritchard
Hall A	
<b>14:00–15:30</b> <i>Chairpersons</i>	Abstract session 3: New technologies in Immunogenetics Eric Spierings, Jakob Nilsson
Hall C	
14:00-15:30	Abstract session 4: Immunogenetics in organ transplantation 1
Chairpersons	Caroline Wehmeier, Claudia Lehmann





Hall B		
16:00-17:30	Plenary session II Hematopoietic stem cell transplantation (New therapies for acute leukemia: HSCT, CAR-T, Bispec-Ab)	
Chairpersons	Kay Poulton, Pietro Crivello	
16:00–16:30	HSCT Jakob Passweg	
16:30-17:00	B-specific antibody therapy Catherine Thieblemont	
17:00–17:30	CAR-T cells Federico Simonetta	
Hall B		
<b>17:30–18:00</b> Chairperson	Serological nomenclature: update Marcelo Fernández-Viña	
Hall C		
17:30–18:10	Industry symposium: Hansa Biopharma	
Hall A		
17:30-18:10	Industry symposium: Omixon	
Poster Hall		
18.10-20.00	Poster viewing session	





## **WEDNESDAY, MAY 22, 2024**

Hall B	
08:30-10:00	Plenary session III
	HLA immunogenetics and population genetics a combined SIP-EFI session
Chairpersons	Neema Mayor, Alicia Sanchez-Mazas
08:30-09:00	Using genomic data to understand the nature and timescale of selection on HLA genes
	Diogo Meyer
09:00–09:30	<b>Archaic introgression enhanced recognition of HLA-A by first nations Oceanian Natural Killer cells</b> Paul Norman
09:30-10:00	Unveiling HLA population diversity: evolutionary meanings and clinical implications Alicia Sanchez-Mazas

## PARALLEL SESSIONS

Hall B	
10:30-12:00	Special session
Chairpersons	HLA DP models and beyond Jill Hollenbach, Pierre-Antoine Gourraud
10:30-11:00	The importance of Immunopeptidomics data to analyze the immune response Julien Racle
11:00–11:30	The immunopeptidome in HCT – lessons learned from HLA-DP Katharina Fleischhauer
11:30–12:00	MHC class II haplotypes Effie Petersdorf
Hall A	
<b>10:30–12:00</b> <i>Chairpersons</i>	Abstract session 5: Immunogenetics in organ transplantation 2 Valérie Olivier, Jean-Luc Taupin
Hall C	
<b>10:30–12:00</b> Chairpersons	Abstract session 6: MHC evolution, population genetics Natasja de Groot, Steven Mack
Room 4	
12:00-13:15	Presidents meeting
Hall A	

12:10-12:50	Industry symposium: Thermo Fisher Scientific
13:10-13:50	Industry symposium: GenDx

### PARALLEL SESSIONS

Hall B	
14:00-15:30	Young EFI professional special session Al and big data in immunogenetics
Chairpersons	Timo Olieslagers, Arianne Brandsma
14:00–14:30	Al and Big data: friend or foe? Christian Lovis
14:30–15:00	Endeavour in HLA research, an exciting winding path Nicolas Vince
15:00–15:30	Scientific career path; inspiration, collaboration and commitment Sandra Tafulo





Room K	
14:00-15:30	Teaching session 3
Charian	KIR in solid organ and hematopoietic stem cell transplantation
Chairpersons	Paul Norman, Stéphane Buhler
14:00-14:30	The KIR system
14.20 15.00	Paul Norman
14:30–15:00	KIRs in solid organ transplantation Alice Koenig
15:00-15:30	KIRs in hematopoietic stem cell transplantation
	Stéphane Buhler
Hall A	
14:00–15:30 Chairpersons	Abstract session 7: Hematopoietic stem-cell transplantation (HSCT) Nina Svetlitzky, Katarzyna Bogunia-Kubik
Chulipersons	Nina Svetilizký, Katarzyna Bogulila-Kubik
Hall C	
14:00-15:30	Abstract session 8: Autoimmunity, Infection, Reproduction & Cancer
Chairpersons	Danillo Augusto, Fatma Oğuz
Hall B	
16:00-17:30	Plenary session IV
Chairpersons	Giving life- bone marrow / solid organ donors Joannis Mytilineos, TBA
chanpersons	
16:00–16:30	The DKMS studies
16:30–17:00	Johannes Schetelig One organ for every recipient
10.30-17.00	Constanca Figueiredo
17:00-17:30	The view and strategy of WHO
	Efstratios (Stratos) Chatzixiros
Hall B	EEI models coromony
<b>17:30–18:00</b> <i>Chairperson</i>	EFI medals ceremony Ann-Margaret Little
Hall B	
18:00-19:00	EFI General Assembly





## **THURSDAY, MAY 23, 2024**

Hall B	
08:30-10:00	Best abstract session
Chairpersons	Marco Andreani, Luca Vago
10:30-12:00	Plenary session V Antigen presentation and neoantigens
Chairpersons	Lotte Wieten, Esteban Arrieta-Bolaños
10:30–11:00	<b>Deciphering the properties of antitumor T cells in solid cancers</b> Giacomo Oliveira
11:00–11:30	Lymphatic vessels as immunomodulators in cancer Stéphanie Hugues
11:30–12:00	Antigen discovery for the development of personalized cancer immunotherapy Michal Bassani-Sternberg
12:00-12:30	Closing Ceremony
Chairpersons	Marco Andreani, Sylvie Ferrari-Lacraz
12:00-12:15	19 <sup>th</sup> IHIW presentation Jon Van Rood award & best abstracts award
12:15–12:30	Committee chair: Steven Marsh
	Best poster awards
	Committee chair: Stefan Schaub
12:30-13:00	Lecture
	The world of exoplanets Monika Lendl
	Remarks

Welcome to Prague and final conclusions





## LIST OF POSTERS

## **AUTOIMMUNITY, INFECTION, REPRODUCTION & CANCER**

### P1 | Exploring the germline diversity of various macaque B-cell receptor regions

Susan Ott<sup>1</sup>, Ngoc Giang Le<sup>1</sup>, Nanine de Groot<sup>1</sup>, Marit van der Wiel<sup>1</sup>, Jesse Mittertreiner<sup>1</sup>, Natasja de Groot<sup>1</sup>, Jesse Bruijnesteijn<sup>1</sup> and Ronald E. Bontrop<sup>1</sup>

<sup>1</sup>Biomedical Primate Research Centre, Netherlands

### P2 | HLA allele frequencies and susceptibility to Bullous Pemphigoid in a group of 116 Italian patients Marco Andreani<sup>1</sup>, Feliciana Mariotti<sup>2</sup>, Anna Pira<sup>2</sup>, Giuseppe Testa<sup>1</sup>, Priscilla Caputi<sup>2</sup>, Mariarosa Battarra<sup>1</sup>, Tiziana Galluccio<sup>3</sup>, Franco Locatelli<sup>4</sup> and Giovanni Di Zenzo<sup>2</sup>

<sup>1</sup>Laboratorio di Immunogenetica dei Trapianti, Ospedale Pediatrico Bambino Gesù, Roma, Italy; ; <sup>2</sup>Laboratorio di Biologia Molecolare e Cellulare, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Roma, Italy; <sup>3</sup>Laboratorio di Immunogenetica dei Trapianti, Ospedale Pediatrico Bambino Gesù, Roma, Italy; <sup>4</sup>Dipartimento Onco-Ematologia e Terapia Cellulare e Genica, Ospedale Pediatrico Bambino Gesù, Roma, Italy

### P3 | Genetic Variants associated with Narcolepsy

#### Steven Jervis<sup>1</sup>, Kay Poulton<sup>1</sup>, Antony Payton<sup>2</sup> and Arpana Verma<sup>2</sup>

<sup>1</sup>Manchester Transplantation Laboratory, United Kingdom; <sup>2</sup>University of Manchester, United Kingdom

## P4 | NKG2D receptor and MICA and MICB ligand polymorphism in CALR mutation – driven Myeloproliferative Neoplasms

#### Milena Ivanova<sup>1</sup>, Angelina Mladenova<sup>1</sup>, Gergana Tsvetkova<sup>2</sup>, Evgueniy Hadjiev<sup>2</sup> and Velizar Shivarov<sup>3</sup>

<sup>1</sup>Department of Clinical Immunology, Alexandrovska University Hospital, Medical University Sofia, Sofia, Bulgaria; <sup>2</sup>Department of Clinical Hematology, Alexandrovska University Hospital, Medical University Sofia, Sofia, Bulgaria; <sup>3</sup>Department of Experimental Research, Medical University Pleven, Pleven, Bulgaria

### P5 | A non-invasive method for fetal trophoblast HLA typing in early pregnancy

## Liseanne J. van T. Hof<sup>1</sup>, Hanneke M. Kapsenberg<sup>1</sup>, Jos J.M. Drabbels<sup>1</sup>, Michael Eikmans<sup>1</sup>

#### and Marie-Louise L.P. van der Hoorn<sup>2</sup>

<sup>1</sup>Department of Immunology, Leiden University Medical Center, Leiden, Netherlands; <sup>2</sup>Department of Obstetrics and Gynaecology, Leiden University Medical Center, Leiden, Netherlands

## P6 | Differential Modulation of Mutant CALR and JAK2 V617F-Driven Oncogenesis by HLA Genotype in Myeloproliferative Neoplasms

## Velizar Shivarov<sup>1</sup>, Gergana Tsvetkova<sup>2</sup>, Ilina Micheva<sup>3</sup>, Evgueniy Hadjiev<sup>2</sup>, Jasmina Petrova<sup>4</sup>, Anela Ivanova<sup>4</sup>, Galja Madjarova<sup>4</sup> and Milena Ivanova<sup>5</sup>

<sup>1</sup>Department of Experimental Research, Medical University Pleven, Pleven, Bulgaria; <sup>2</sup>Department of Clinical Hematology, Alexandrovska University Hospital, Medical University Sofia, Sofia, Bulgaria; <sup>3</sup>Department of Clinical Hematology, Saint Marina University Hospital, Medical University Varna, Varna, Bulgaria; <sup>4</sup>Department of Physical Chemistry, Faculty of Chemistry and Pharmacy, Sofia University "St. Kl. Ohridski", Bulgaria, Bulgaria; <sup>5</sup>Department of Clinical Immunology, Alexandrovska University Hospital, Medical University Sofia, Sofia, Bulgaria

### P7 | Effects of HLA-G molecules in Primary Biliary Cholangitis: The Sardinian Experience

Caterina Mereu<sup>1</sup>, Michela Lorrai<sup>1</sup>, Stefano Mocci<sup>1</sup>, Roberto Littera<sup>2</sup>, Michela Miglianti<sup>3</sup>, Celeste Sanna<sup>1</sup>, Michela Murgia<sup>1</sup>, Meropi Plousiou<sup>1</sup>, Chiara Cocco<sup>1</sup>, Alessia Mascia<sup>4</sup>, Marina Serra<sup>4</sup>, Sara Lai<sup>2</sup>, Erika Giuressi<sup>2</sup>, Maria Conti<sup>5</sup>, Cinzia Balestrieri<sup>5</sup>, Giancarlo Serra<sup>5</sup>, Francesco Pes<sup>5</sup>, Teresa Zolfino<sup>6</sup>, Andrea Perra<sup>3</sup>, Luchino Chessa<sup>3</sup> and Sabrina Rita Giglio<sup>2</sup>

<sup>1</sup>Medical Genetics Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; <sup>2</sup>Medical Genetics Unit, R. Binaghi Hospital, Local Public Health and Social Care Unit of Cagliari, Cagliari, Italy; <sup>3</sup>Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; <sup>4</sup>Section of Pathology, Department of Biochemical Sciences, University of Cagliari, Cagliari, Italy; <sup>5</sup>Liver Unit, University Hospital, Monserrato, Cagliari, Italy; <sup>6</sup>Gastroenterology Unit, ARNAS Brotzu, Cagliari, Italy

### P8 | Role of HLA-G in Sardinian Idiopatic Pulmonary Fibrosis patients

### Michela Lorrai<sup>1</sup>, Caterina Mereu<sup>1</sup>, Stefano Mocci<sup>1</sup>, Roberto Littera<sup>2</sup>, Silvia Deidda<sup>3</sup>, Celeste Sanna<sup>1</sup>, Michela Murgia<sup>1</sup>, Meropi Plousiou<sup>1</sup>, Gaia Maria Tosone<sup>1</sup>, Alessia Mascia<sup>4</sup>, Marina Serra<sup>4</sup>, Sara Lai<sup>2</sup>, Erika Giuressi<sup>2</sup>, Andrea Perra<sup>5</sup> and Sabrina Rita Giglio<sup>2</sup>

<sup>1</sup>Medical Genetics Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; <sup>2</sup>Medical Genetics Unit, R. Binaghi Hospital, Local Public Health and Social Care Unit of Cagliari, Cagliari, Italy; <sup>3</sup>Pneumology Unit, R. Binaghi Hospital, Sardegna, Italy; <sup>4</sup>Section of Pathology, Department of Biochemical Sciences, University of Cagliari, Cagliari, Italy; <sup>5</sup>Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy





### P9 | Islet Antibodies Among North Indian Type 1 Diabetes Patients: Prevalence and Persistence Pattern Uma Kanga<sup>1</sup>, Shreya Sharma<sup>2</sup>, Alpesh Goyal<sup>2</sup> and Nikhil Tandon<sup>2</sup>

<sup>1</sup>Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, India; <sup>2</sup>Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, India

Among this T1D cohort, 74.9% were HLA-DRB1\*03 positive while only 30.6% were DRB1\*04 positive. Significant associations of DRB1\*03 alleles with presence of GAD antibodies and DRB1\*04 alleles with ZnT8 antibody positivity were observed. Antibody persistence did not reflect any HLA association. A unique antibody profile was observed in this T1D cohort.

## P10 | Nanopore sequencing reveals high resolution HLA alleles associated to autoimmune neutropenia in early childhood

Kirstine Kløve-Mogensen<sup>1</sup>, Thure Mors Haunstrup<sup>1</sup>, Tania Nicole Masmas<sup>2</sup>, Andreas Glenthøj<sup>3</sup>, Petter Höglund<sup>4</sup>, Henrik Hasle<sup>5</sup>, Kaspar Rene Nielsen<sup>1</sup> and Rudi Steffensen<sup>1</sup>

<sup>1</sup>Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark; <sup>2</sup>Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; <sup>3</sup>Department of Hematology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark; <sup>4</sup>Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden; <sup>5</sup>Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark

### P11 | Detection and identification of platelet antibodies using a Luminex bead assay Nataša Katalinić<sup>1</sup>, Tajana Crnić Marčetić<sup>2</sup>, Sandra Šever Šušnjar<sup>2</sup>, Marijana Duhović<sup>2</sup> and Sanja Balen<sup>1</sup>

<sup>1</sup>Tissue Typing Laboratory, CHC Rijeka; Department of Clinical Laboratory Diagnostics, Medical Faculty Rijeka, Croatia; <sup>2</sup>Tissue Typing Laboratory, Clinical Hospital Center Rijeka, Croatia

## P12 | Distinguishing Anti-3-hydroxy-3-methylglutaryl-CoA reductase Immune-Mediated Necrotizing Myopathy from Non-Immune-Mediated Statin Myotoxicity: The Role of HLA-DRB1\*11:01 Association

## Diana Prieto-Peña<sup>1</sup>, Nerea Mota-Pérez<sup>2</sup>, J. Gonzalo Ocejo<sup>2</sup>, Cristina Corrales-Selaya<sup>1</sup>, Carmen García-Ibarbia<sup>3</sup>, Verónica Pulito-Cueto<sup>4</sup>, Raquel López-Mejías<sup>4</sup>, Ricardo Blanco<sup>1</sup> and José Luis Hernández<sup>3</sup>

<sup>1</sup>Rheumatology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain; <sup>2</sup>Immunology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain; <sup>3</sup>Internal Medicine Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain; <sup>4</sup>IDIVAL Health Research Institute of Cantabria, Santander, Spain

Myotoxicity and controls showed no significant differences in HLA-DRB1\*11 allele distribution. Our findings suggest a strong association between HLA-DRB1\*11, particularly HLA-DRB1\*11:01, and anti-HMGCR IMNM, not observed in non-immune-mediated statin myotoxicity. Identifying HLA-DRB1\*11:01 may help identify those at high risk of anti-HMGCR IMNM.

## P13 | The impact of HLA-DRB1 alleles in a Hellenic Pediatric Onset Multiple Sclerosis cohort: Implications on clinical and neuroimaging profile.

## Charalampos Skarlis<sup>1</sup>, Nikolaos Markoglou<sup>2</sup>, Maria Gontika<sup>3</sup>, Petros Prapas<sup>1</sup>, Maria Kotsari<sup>1</sup>, Artemios Artemiadis<sup>4</sup>, Maria-Roser Pons<sup>5</sup>, Leonidas Stefanis<sup>2</sup>, Marinos Dalakas<sup>6</sup>, George Chrousos<sup>7</sup> and Maria Anagnostouli<sup>2</sup>

<sup>1</sup>Immunogenetics Laboratory, First Department of Neurology, School of Medicine, NKUA, Aeginition University Hospital, Greece; <sup>2</sup>First Department of Neurology, School of Medicine, NKUA, Aeginition University Hospital, Greece; <sup>3</sup>Penteli Children's Hospital, Greece; <sup>4</sup>Neurology Department, Cyprus University, Greece; <sup>5</sup>First Department of Pediatrics, School of Medicine, NKUA, Agia Sofia University Hospital, Greece; <sup>6</sup>Neuroinmunology Laboratory, Department of Pathophysiology School of Medicine, NKUA, Greece; <sup>7</sup>Clinical and Translational Research Unit in Endocrinology, NKUA, Greece

### P14 | Availability of CD36 negative platelets and the importance of CD36 Donor Screening Sarah Petermann<sup>1</sup>, Brigitte Flesch<sup>2</sup>, Beate Kirchharz<sup>3</sup>, Martina Wessiepe<sup>4</sup>, Svenja Woestmann<sup>1</sup> and Alexander Carbol<sup>1</sup>

<sup>1</sup>German Red Cross Blood Service Rhineland-Palatinate and Saarland, Bad Kreuznach, Germany; <sup>2</sup>German Red Cross Blood Service West, Hagen, Germany; <sup>3</sup>German Red Cross Blood Service West, Ratingen, Germany; <sup>4</sup>University Hospital RWTH Aachen, Transfusion Medicine, Aachen, Germany;

#### P15 | Investigation of the interaction of HLA-G with natural killer inhibitory receptors in colorectal cancers Ezgi Dincer<sup>1</sup>, Fatma Kaya Dagistanli<sup>2</sup>, Kivanc Derya Peker<sup>3</sup>, Damlanur Sakiz<sup>4</sup>, Demet Kivanc Izgi<sup>1</sup>, Hayriye Senturk Ciftci<sup>1</sup> and Fatma Savran Oguz<sup>1</sup>

<sup>1</sup>Istanbul University, Istanbul Faculty of Medicine, Institute of Health Sciences, Department of Medical Biology, Turkey; <sup>2</sup>Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Biology, Turkey; <sup>3</sup>Hisar Intercontinental Hospital, Department of General Surgery, Turkey; <sup>4</sup>University of Health Sciences Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Pathology Clinic, Turkey;

### P16 | Potential actionable somatic variants in Chronic Lymphocytic Leukemia

**Gurvinder Kaur<sup>1</sup>, Ayushi Jain<sup>1</sup>, Kamaljeet Singh<sup>1</sup>, Lingaraja Jena<sup>1</sup>, Ajay Gogia<sup>2</sup>, Atul Sharma<sup>2</sup> and Ritu Gupta<sup>1</sup>** <sup>1</sup>Lab Oncology, Dr BRAIRCH, All India Institute of Medical Sciences, New Delhi, India; <sup>2</sup>Medical Oncology, Dr BRAIRCH, All India Institute of Medical Sciences, New Delhi, India





### P17 | Two-locus haplotypes HLA-DRB1~IL-17A and HLA-DRB1~IL-17F – protectors of rheumatoid arthritis in the Russian population

Daria Shmelkova<sup>1</sup>, Daria Stashkevich<sup>1</sup>, Tatiana Suslova<sup>1</sup>, Inessa Devald<sup>1</sup> and Alexandra L. Burmistrova<sup>1</sup> <sup>1</sup>Chelyabinsk State University, Russia;

### P18 | Genetic Insights into COVID-19 Severity: HLA-E and HLA-G Alleles as Potential Determinants Cigdem Kekik<sup>1</sup>, Sonay Temurhan<sup>1</sup>, Yeliz Ogret<sup>1</sup>, Demet Kivanc Izgi<sup>1</sup>, Behnoush Nasr Zanjani<sup>2</sup>, Fatma Betul Oktelik<sup>3</sup>, Fatma Savran Oguz<sup>1</sup>, Murat Kose<sup>4</sup> and Gunnur Deniz<sup>3</sup>

<sup>1</sup>Department of Medical Biology, HLA Laboratory, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; <sup>2</sup>Institute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Turkey; <sup>3</sup>Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey; <sup>4</sup>Department of Internal Medicine, Division of General Internal Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey

### P19 Understanding the role of HLA-G polymorphism in causing susceptibility to cervical cancer Ritu Aggarwal<sup>1</sup>, Tanvi Bhatia<sup>1</sup>, Arshiya Mehra<sup>1</sup> and Vanita Suri<sup>2</sup>

<sup>1</sup>Department of Immunopathology, PGIMER, Chandigarh, India; <sup>2</sup>Department of Obstetrics and Gynecology, PGIMER, Chandigarh, India

#### P20 Sudden Cardiac Death and HLA variation – report from the initial phase of investigations Martin Petrek<sup>1</sup>, Katerina Sikorova<sup>2</sup>, Lenka Kocourkova<sup>3</sup>, Martin Dobias<sup>2</sup> and Jana Petrkova<sup>1</sup> <sup>1</sup>University Hospital Olomouc and Faculty of Medicine and Dentistry Palacky University Olomouc, Czechia; <sup>2</sup>University Hospital Olomouc, Czechia; <sup>3</sup>Faculty of Medicine and Dentistry Palacky University Olomouc, Czechia

## P21 Association between HLA-markers and the COVID-19 severity in residents of Saint-Petersburg, Russia Irina Pavlova<sup>1</sup>, Elena Kuzmich<sup>1</sup>, Elena Shilova<sup>1</sup>, Tatyana Glazanova<sup>1</sup> and Ludmila Bubnova<sup>1</sup>

<sup>1</sup>Russian Research Institute of Hematology and Transfusiology, Russia

### P22 | Haplotype frequencies and linkage disequilibrium of HLA-DRB1 and TNFa SNPs in Russian patients with irritable bowel syndrome living in the Chelyabinsk region of the Russian South Urals Daria Stashkevich<sup>1</sup>, Tatiana Suslova<sup>1</sup> and Alexandra L. Burmistrova<sup>1</sup>

<sup>1</sup>Chelyabinsk State University, Russia;

#### P23 | HLA characterization of 115 type 1 diabetes children by next generation sequencing Eulalia Catamo<sup>1</sup>, Valentina Bazzo<sup>2</sup>, Valentina Moro<sup>2</sup>, Antonietta Robino<sup>1</sup>, Luana Aldegheri<sup>1</sup>, Andrea Conti<sup>1</sup>, Gianluca Tornese<sup>1</sup> and Elena Bevilacgua<sup>2</sup>

<sup>1</sup>Institute for Maternal and Child Health—IRCCS "Burlo Garofolo", Trieste , Italy; <sup>2</sup>Tissue Typing Laboratory, Transfusion Medicine Department, University Hospital (ASUGI), Trieste, Italy

### P24 | Evaluation of Clinical-Laboratory Parameters in Patients with Autoimmune Renal Disease After Transplantation

### Vasiliki Kitsiou<sup>1</sup>, Elisavet Kontou<sup>1</sup>, Petros Mantzios<sup>1</sup>, Glykeria Tsouka<sup>2</sup>, Stella Pomoni<sup>1</sup>, Theofilos Athanassiades<sup>1</sup>, Katerina Tarassi<sup>1</sup>, Vasileios Vougas<sup>3</sup>, Maria Darema<sup>2</sup> and Alexandra Tsirogianni<sup>1</sup>

<sup>1</sup>Immunology-Histocompatibility Department, Evangelismos General Hospital, Athens, Greece; <sup>2</sup>Nephrology Department, Evangelismos General Hospital, Athens, Greece; <sup>3</sup>Department of General Surgery and Transplant Unit, Evangelismos General Hospital, Athens, Greece

P25 | TNFA G308A polymorphism in COVID-19 Russian patients of the Chelyabinsk region Svetlana Balandina<sup>1</sup>, Svetlana Belyaeva<sup>1</sup> and Daria Stashkevich<sup>1</sup> <sup>1</sup>Chelyabinsk State University, Russia;

### **BIOINFORMATICS, DATA ANALYSIS IN IMMUNOGENETICS**

P26 Uncovering the immunogenetic landscape of 2609 Multiple Sclerosis patients of the OFSEP-HD cohort Julien Paris<sup>1</sup>, Sonia Bourguiba-Hachemi<sup>1</sup>, Romain Casey<sup>2</sup>, Nicolas Vince<sup>1</sup> and Pierre-Antoine Gourraud<sup>1</sup> <sup>1</sup>Nantes Université, CHU Nantes I, INSERM, CR2TI, UMR 1064, F-44000, Nantes, France; <sup>2</sup>OFSEP, Research Center in Neurosciences of Lyon, INSERM 1028 and CNRS UMR 5292, F-69003 Lyon, France

### P27 | HLA-DRB3, DRB4, DRB5: Three Loci or a Single Locus?

Nickolai Alexandrov<sup>1</sup>, Ting Wang<sup>1</sup>, Brian Nadon<sup>1</sup>, Lindley Blair<sup>1</sup>, Yuki Saito<sup>1</sup> and David Sayer<sup>2</sup> <sup>1</sup>Thermo Fisher Scientific Inc., United States; <sup>2</sup>Thermo Fisher Scientific Inc., Australia





## P28 | Pan-major histocompatibility complex and pan-leukocyte receptor complex reference graphs containing 246 fully contiguous phased sequences enable precision immunology

## Liza Huijse<sup>1</sup>, Solomon M. Adams<sup>2</sup>, Joshua N. Burton<sup>2</sup>, Julianne K. David<sup>2</sup>, Russell S. Julian<sup>2</sup>, Galit Meshulam-Simon<sup>2</sup>, Harry Mickalide<sup>2</sup>, Bersabeh D. Tafesse<sup>2</sup>, Verónica Calonga-Solís<sup>3</sup>, Ivan Rodrigo Wolf<sup>3</sup>, Ashby J. Morrison<sup>4</sup>, Danillo G. Augusto<sup>3</sup> and Solomon Endlich<sup>2</sup>

<sup>1</sup>Base5 Genomics, Inc., Netherlands; <sup>2</sup>Base5 Genomics, Inc., United States; <sup>3</sup>The University of North Carolina at Charlotte, United States; <sup>4</sup>Stanford University, United States

## P29 | A bioinformatic pipeline to assemble complete genomes and to unravel phased immune regions in rhesus macaques using long reads

Ngoc Giang Le<sup>1</sup>, Jesse Mittertreiner<sup>1</sup>, Susan Ott<sup>1</sup>, Nanine de Groot<sup>1</sup>, Marit van der Wiel<sup>1</sup>, Natasja de Groot<sup>1</sup>, Jesse Bruijnesteijn<sup>1</sup> and Ronald E. Bontrop<sup>1</sup>

<sup>1</sup>Biomedical Primate Research Centre, Netherlands;

### P30 | HLAtools: an R Package for HLA Region Informatics

**Ryan Nickens<sup>1</sup>, Livia Tran<sup>2</sup>, Leamon Crooms<sup>3</sup> and Steven Mack<sup>2</sup>** <sup>1</sup>Lafayette College, Easton, PA, United States; <sup>2</sup>University of California, San Francisco, United States; <sup>3</sup>University of Arizona, United States

#### P31 | epiArt: A graphical Epitope Amino acid Repertoire Translation of HLA allele disparities Henry Loeffler-Wirth<sup>1</sup>, Claudia Lehmann<sup>2</sup>, Nils Lachmann<sup>3</sup> and Ilias Doxiadis<sup>2</sup>

<sup>1</sup>Interdisciplinary Centre for Bioinformatics, IZBI, Leipzig University, Germany; <sup>2</sup>Laboratory for Transplantation Immunology, Institute for Transfusion Medicine, University Hospital Leipzig, Germany; <sup>3</sup>Institute for Transfusion Medicine, H & I Laboratory, Charité-Universitätsmedizin, Germany

### P32 | epiTOol: A browser-based HLA epitope (mis)matching application for small to large cohorts Henry Loeffler-Wirth<sup>1</sup>, Nils Lachmann<sup>2</sup>, Claudia Lehmann<sup>3</sup> and Ilias Doxiadis<sup>3</sup>

<sup>1</sup>Interdisciplinary Centre for Bioinformatics, IZBI, Leipzig University, Germany; <sup>2</sup>Institute for Transfusion Medicine, H & I Laboratory, Charité-Universitätsmedizin, Germany; <sup>3</sup>Laboratory for Transplantation Immunology, Institute for Transfusion Medicine, University Hospital Leipzig, Germany

## P33 | Structural and dynamic analyses of the differential binding of the hypoxia-inducible factor-1 (HIF1) into the HF1 regulatory elements at coding region of the HLA-G gene

Cinthia Alves<sup>1</sup> and Eduardo Donadi<sup>1</sup>

<sup>1</sup>Ribeirão Preto Medical School, University of São Paulo, Brazil;

## P34 Using biobank data to identify full-length haplotypes of 15 MHC genes in the Finnish population Jonna Clancy<sup>1</sup>, Silja Tammi<sup>2</sup>, Jukka Partanen<sup>2</sup> and Satu Koskela<sup>1</sup>

<sup>1</sup>Finnish Red Cross Blood Service Biobank, Finland; <sup>2</sup>Finnish Red Cross Blood Service, R&D, Finland

#### P35 | A new bioinformatics tool providing robust methods for HLA case-control studies Enrique Alanis<sup>1</sup>, Diana Alcantara<sup>2</sup>, Alicia Sanchez-Mazas<sup>1</sup> and José Manuel Nunes<sup>1</sup>

<sup>1</sup>Department of Genetics and Evolution, University of Geneva, Switzerland; <sup>2</sup>Brighton and Sussex Medical School, United Kingdom

## P36 | Modelling an international donor recruitment strategy in a collaborative pilot study between a UK and Indian donor registry

#### Michaela Agapiou<sup>1</sup>, Richard H.L. Natarajan<sup>2</sup>, Claudia Rutt<sup>3</sup>, Sumati Misra<sup>3</sup>, James Robinson<sup>1</sup>, Nezih Cereb<sup>3</sup> and Steven G.E. Marsh<sup>1</sup>

<sup>1</sup>Anthony Nolan Research Institute, London, United Kingdom; UCL Cancer Institute, London, United Kingdom; <sup>2</sup>Anthony Nolan Research Institute, London, United Kingdom; <sup>3</sup>DATRI Blood Stem Cell Donors Registry, Chennai, India, United Kingdom

## P37 | HLA-DRB3, -DRB4, -DRB5 allele frequencies of 12 populations from Germany, United Kingdom, Poland, Chile, United States, India, and South Africa

**Susanne Seitz<sup>1</sup>, Karen Ende<sup>1</sup>, Katharina Daniel<sup>2</sup>, Vinzenz Lange<sup>2</sup> and Alexander H. Schmidt<sup>1</sup>** <sup>1</sup>DKMS Group, Kressbach 1, 72072 Tübingen, Germany; <sup>2</sup>DKMS Life Science Lab, St. Petersburger Str.2, 01069 Dresden, Germany





P38 | IDS: a clinical decision support system for kidney transplantation with precision medicine tools to enhance bedside manners

Olivia Rousseau<sup>1</sup>, Estelle Geffard<sup>1</sup>, Emmanuelle Papuchon<sup>1</sup>, Axelle Durand<sup>1</sup>, Sirine Sayadi<sup>1</sup>, Chadia Ed-Driouch<sup>1</sup>, Rokhaya Ba<sup>1</sup>, Stanislas Demuth<sup>1</sup>, Alexandre Loupy<sup>2</sup>, Sophie Brouard<sup>1</sup>, Magali Giral<sup>1</sup>, Carmen Lefaucheur<sup>3</sup>, Emmanuel Morelon<sup>4</sup>, Lionel Couzi<sup>5</sup>, Nassim Kamar<sup>6</sup>, Moglie Le Quintrec<sup>7</sup>, Nicolas Vince<sup>1</sup>, Sophie Limou<sup>1</sup> and Pierre-Antoine Gourraud<sup>1</sup>

<sup>1</sup>Nantes Université, CHU Nantes, Ecole Centrale de Nantes, INSERM, CR2TI, UMR 1064, ITUN, Nantes, France; <sup>2</sup>Paris Translational Research Center for Organ Transplantation, France; <sup>3</sup>Assistance Publique-Hôpitaux de Paris, France; <sup>4</sup>Université de Lyon Service de néphrologie, France; <sup>5</sup>CHU de Bordeaux, France; <sup>6</sup>CHU de Toulouse, France; <sup>7</sup>CHU de Montpellier, France

P39 | Evaluating HLA imputation clinical utility compared to classical genotyping

Nayane S. B. Silva<sup>1</sup>, Sonia Bourguiba-Hachemi<sup>1</sup>, Nathalie Bouatlaoui<sup>1</sup>, Camille Plédet<sup>1</sup>, Roxane van Olden<sup>1</sup>, Sophie Limou<sup>1</sup> and Nicolas Vince<sup>1</sup>

<sup>1</sup>Nantes Université, INSERM, Ecole Centrale Nantes, CHU Nantes, CR2TI, UMR 1064, Nantes, France

P40 | PRIMUS: A distributed web application architecture to benchmark sets of analytics based on reuse of multi-source clinical research data in multiple sclerosis under the umbrella of precision medicine Igor Faddeenkov<sup>1</sup>, Stanislas Demuth<sup>1</sup>, Joëlle Martin-Gauthier<sup>1</sup>, Julien Paris<sup>1</sup>, Gilles Edan<sup>2</sup>, David Laplaud<sup>1</sup> and Pierre-Antoine Gourraud<sup>1</sup>

<sup>1</sup>Nantes Université, CHU Nantes, INSERM, CR2TI, UMR 1064, ITUN, Nantes, France; <sup>2</sup>Department of Neurology, University Hospital of Rennes, France

P41 | Neoantigen Recognition by HLA class I and II: Relationship between Hematological malignancies and specific HLA distribution in Greek Population

**Panagiotis Mallis<sup>1</sup>, Alexandra Siorenta<sup>1</sup>, Erasmia Stamathioudaki<sup>1</sup>, Vasiliki Vrani<sup>1</sup> and Georgios Paterakis<sup>1</sup>** <sup>1</sup>Immunology Department & National Tissue Typing Center, General Hospital of Athens "G. Gennimatas", Athens, Greece

**P42** | Limited Incremental Value of Routine Flow Crossmatch Prior To Kidney Transplantation Franz Fenninger<sup>1</sup>, Bronwyn Baillie<sup>1</sup>, Karen Sherwood<sup>1</sup>, Jenny Tran<sup>1</sup>, James Lan<sup>1</sup> and Paul Keown<sup>1</sup> <sup>1</sup>Dept. of Medicine, University of British Columbia, Vancouver, BC, Canada

P43 New measure of interallelic linkage disequilibrium (LD) for highly polymorphic pairs of loci Enrique Alanis<sup>1</sup>, Alicia Sanchez-Mazas<sup>1</sup> and José Manuel Nunes<sup>1</sup> <sup>1</sup>Department of Genetics and Evolution, University of Geneva, Switzerland

P44 | Structural Insights into the CTLA-4 T17A Signal Peptide Mutation Cinthia Alves<sup>1</sup>, Rafaela Miranda Barbosa<sup>1</sup> and Eduardo Donadi<sup>1</sup>

<sup>1</sup>Ribeirão Preto Medical School, University of São Paulo, Brazil;

P45 | PIRCHE application versions 3 and 4 lead to equivalent T cell epitope mismatch scores in solid organ and stem cell transplantation modules Benedict Matern<sup>1</sup> and Matthias Niemann<sup>2</sup> <sup>1</sup>PIRCHE AG, Netherlands; <sup>2</sup>PIRCHE AG, Germany

P46 | Decoding the Influence of Donor Age, HLA Matching, and Relatedness on Hematopoietic Stem Cell Transplantation Success for Leukemia Patients Deniz Akdemir<sup>1</sup> and Yung-Tsi Bolon<sup>1</sup> <sup>1</sup>NMDP, United States

P47 | The Role of HLA class I Alleles in Predicting Hepatocellular Carcinoma Risk and Patient Outcomes: An In-depth TCGA-Based Study

**Shahram Aliyari<sup>1</sup>, Zahra Salehi<sup>2</sup>, Benedikt Brors<sup>3</sup>, Kaveh Kavousi<sup>4</sup> and Mohammad Hossein Norouzi-Beirami<sup>5</sup>** <sup>1</sup>University of Tehran, Kish International Campus, Iran; <sup>2</sup>Tehran University of Medical Sciences, Iran; <sup>3</sup>German Cancer Research Center DKFZ Heidelberg, Germany; <sup>4</sup>Institute of Biochemistry and Biophysics, Iran; <sup>5</sup>Islamic Azad University, Iran

P48 | Revival of the HLA-Cw11 story despite modern typing techniques

Laura Bungener<sup>1</sup>, Niels Kouprie<sup>1</sup>, Magdalena Huberts-Kregel<sup>1</sup>, Annechien Lambeck<sup>1</sup>, Bart-Jan Kroesen<sup>1</sup> and Bouke Hepkema<sup>1</sup>

<sup>1</sup>Transplantation Immunology, Dept. of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Netherlands





### P49 | cPRA.cz – web based algorithm for automated Luminex analysis

Matěj Röder<sup>1</sup>, Vít Svojše<sup>2</sup>, Tomáš Kebrle<sup>2</sup>, Kateřina Jáklová<sup>1</sup>, Jiří Gurka<sup>3</sup>, Petr Raška<sup>3</sup> and Antonij Slavčev<sup>1</sup> <sup>1</sup>Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czechia; <sup>2</sup>Bindworks S.R.O., Czechia; <sup>3</sup>Information Technology Division, Institute for Clinical and Experimental Medicine, Prague, Czechia

## P50 | SNV in MHC Class III Genes. Detection by Exome Sequencing in Samples with Homozygosity in HLA-A~C~B~DRB1~DQB1 loci

Luis Cristovao Porto<sup>1</sup>, Angela Maria Santos<sup>1</sup>, Danielle Secco<sup>1</sup>, Raiana Barbosa<sup>2</sup>, Romulo Oliveira<sup>1</sup>, Antonio Carlos Campos-de-Carvalho<sup>2</sup>, Adriana Carvalho<sup>2</sup>, Daniellii Oliveira<sup>3</sup> and Tais Brunswick<sup>2</sup> <sup>1</sup>Rio de Janeiro State University, Brazil; <sup>2</sup>Federal University of Rio de Janeiro, Brazil; <sup>3</sup>National Cancer Institute, Brazil

### P51 | Argentina's Leap into the cPRA Era: Embracing Transplantation Advancements

Manuel Quirno Costa<sup>1</sup>, Maria Belén Balekjian<sup>1</sup>, Santiago Meinardo Cambra<sup>2</sup> and Gustavo Piccinelli<sup>3</sup> <sup>1</sup>Laboratorio Nacional de Inmunogenética – INCUCAI, Argentina; <sup>2</sup>Freelance Programmer, Argentina; <sup>3</sup>Centro Provincial de Histocompatibilidad – CUCAIBA, Argentina

## P52 | Comparison of two semi-quantitative single antigen bead methods for the detection of anti-HLA antibodies with a machine learning algorithm

### Asimina Fylaktou¹, Georgios Lioulios², Georgios Petasis¹, Artemis Maria Iosifidou³, Myrto Aikaterini Iosifidou³, Georgia Chatzika¹, Evaggelia Sidira¹, Fani Makrovasili¹, Maria Stangou⁴ and Ioannis Theodorou⁵

<sup>1</sup>National Peripheral Histocompatibility Center – Immunology Department, Hippokration General Hospital, Thessaloniki, Greece; <sup>2</sup>Department of Nephrology, 424 Military Hospital, Thessaloniki, Greece; <sup>3</sup>School of Medicine, Aristotle University of Thessaloniki, 45636 Thessaloniki, Greece; <sup>4</sup>Department of Nephrology, Hippokration Hospital, Thessaloniki, Greece; <sup>5</sup>Laboratoire d'Immunologie, Hôpital Robert Debré, Paris, France

## P53 Advancing HLA typing on nanopore sequencing platforms: A novel phasing-based bioinformatics software for high resolution and accuracy

### Jue Wang<sup>1</sup>, Huan Yu<sup>2</sup>, Chen Chen<sup>2</sup>, Jiajie Luo<sup>2</sup> and Hu Wang<sup>2</sup>

<sup>1</sup>Clinical Transfusion Research Center Institute of Blood Transfusion, CAMS & PUMC, Chengdu, Sichuan Province, P.R. China, China; <sup>2</sup>Genetics and Cancer Research Department, Qitan Technology Ltd., Beijing, P.R. China, China

P54 | Laboratory reporting of DQB1\*03:05 (DQ8) and DQB1\*03:19 (DQ7) in UK NEQAS for H&I's external proficiency testing scheme for Coeliac Disease

Amy De'Ath<sup>1</sup> and Deborah Pritchard<sup>1</sup>

<sup>1</sup>UK NEQAS for H&I, United Kingdom

P55 | Performance of participants of UK NEQAS for H&I pharmacogenetics schemes over the last 5 years Amy De'Ath<sup>1</sup> and Deborah Pritchard<sup>1</sup>

<sup>1</sup>UK NEQAS for H&I, United Kingdom

P56 | Enhancing organ transplantation outcomes through standards-compliant software solutions Hamid Ramezanali<sup>1</sup>, Caitlin Haughey<sup>1</sup>, Francesco Vezzi<sup>1</sup>, August Jangerstad<sup>1</sup>, Julia Paschke<sup>1</sup> and Silje Abrante<sup>1</sup> <sup>1</sup>Devyser, Sweden

### P57 | Avocado as a supplement in Afro-Colombian patients with obesity, diabetes and who express the HLA-DQB1\*02:01

Carlos Parga-Lozano<sup>1</sup> and Jim Adolfo Alfaro Ariza<sup>2</sup>

<sup>1</sup>Research and Innovation Center CIIS and Fundacion Universitaria del Area Andina, Colombia; <sup>2</sup>Fundación Universitaria del Área Andina, Colombia

## HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT)

## P58 | Effect of Killer-cell Immunoglobulin-like Receptors and their cognate HLA ligands on tumor disease-free survival after allogeneic hematopoietic stem cell transplantation

Jacek Nowak<sup>1</sup>, Agnieszka Witkowska<sup>1</sup>, Agnieszka Malinowska<sup>1</sup>, Klaudia Nestorowicz-Kałużna<sup>2</sup>, Elżbieta Graczyk-Pol<sup>1</sup>, Anna Flaga<sup>1</sup>, Urszula Szlendak<sup>1</sup>, Anna Wnorowska<sup>1</sup>, Aleksandra Wawiórko<sup>1</sup>, Wiktoria Szwajkowska<sup>1</sup> and Agnieszka Gawron<sup>1</sup>

<sup>1</sup>Institute of Hematology and Transfusion Medicine, Poland; <sup>2</sup>Organization and Coordination Center for Transplantation "POLTRANSPLANT", Poland

## P59 | HLA-loss relapse detection using NGS data from standard HLA genotyping in haploidentical stem cell transplantation

## Milena Vraná<sup>1</sup> and Radek Plachy<sup>1</sup>

<sup>1</sup>Institute of Hematology and Blood Transfusion, Prague, Czechia





## P60 | HLA Loss detection after Haplo-identical Hematopoietic Stem Cell Transplantation using a Next Generation Sequencing based specific approach.

### Alexandre Walencik<sup>1</sup>, Laetitia Anguetil<sup>1</sup> and Mehdi Alizadeh<sup>2</sup>

<sup>1</sup>Laboratoire HLA Nantes, EFS Centre Pays de la Loire, France; <sup>2</sup>Unité de Production de Réactifs (UPR), EFS Bretagne, France

## P61 | DSA determination and eplet mismatches analysis in pediatric patients affected by hemoglobinopathies treated with haploidentical hematopoietic stem cell transplantation

Paola Giustiniani<sup>1</sup>, Federica Galaverna<sup>2</sup>, Pietro Merli<sup>2</sup>, Antonio Giuseppe Bianculli<sup>1</sup>, Marco Becilli<sup>2</sup>, Roberto Carta<sup>2</sup>, Emilia Boccieri<sup>2</sup>, Maria Troiano<sup>1</sup>, Rita Maria Pinto<sup>2</sup>, Mariarosa Battarra<sup>1</sup>, Marco Andreani<sup>1</sup> and Franco Locatelli<sup>2</sup> <sup>1</sup>Laboratorio di Immunogenetica dei Trapianti, Ospedale Pediatrico Bambino Gesù, Roma, Italy; <sup>2</sup>Dipartimento di Oncologia, Ematologia, Trapianto e Terapia Cellulare e Genica, Ospedale Pediatrico Bambino Gesù, Roma, Italy

## P62 | Eplets mismatched analysis in a group of pediatric patients affected by hematological malignant diseases treated with haploidentical HSCT

Marco Andreani<sup>1</sup>, Pietro Merli<sup>2</sup>, Giuseppe Testa<sup>1</sup>, Maria Troiano<sup>1</sup>, Tiziana Galluccio<sup>1</sup>, Rita Maria Pinto<sup>2</sup> and Franco Locatelli<sup>2</sup>

<sup>1</sup>Laboratorio di Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy; <sup>2</sup>Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy

#### P63 | HLA-DQ heterodimers and graft failure after haploidentical stem cell transplantation in patients with acute leukemia

#### Ekaterina Khamaganova<sup>1</sup> and Mikhail Drokov<sup>1</sup>

<sup>1</sup>National Medical Research Center for Hematology, Russia

### P64 | Validation and implementation of HLA loss relapse detection by NGS-based HLA typing Elena Gómez Massa<sup>1</sup>, Sílvia Mantecón-Ferrer<sup>1</sup>, Laura Mongay Berdet<sup>1</sup>, Josefa Caro Martínez<sup>1</sup>, M. Luz Uria-Oficialdegui<sup>2</sup>, Marta Peña Domingo<sup>3</sup>, Maria Huguet Mas<sup>4</sup>, Cecilia Gonzalez<sup>5</sup>, Francesc Rudilla-Salvador<sup>1</sup> and María José Herrero<sup>1</sup>

<sup>1</sup>Histocompatibility and Immunogenetics Laboratory, Blood and Tissue Bank, Barcelona, Spain; <sup>2</sup>Pediatric Oncology and Hematology Department, Hospital Infantil Vall d'Hebron, Barcelona, Spain; <sup>3</sup>Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; <sup>4</sup>Hematology Department, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; <sup>5</sup>Immunohematology Laboratory, Blood and Tissue Bank, Barcelona, Spain

## P65 | Impact of KIR genotype on clinical outcome of Hematopoietic Stem Cell transplants: a single center experience

Francesco Ingrassia<sup>1</sup>, Alice Pecoraro<sup>1</sup>, Maria Blando<sup>1</sup>, Alessia Angela Corica<sup>1</sup>, Floriana Di Paola<sup>1</sup>, Giuseppe Davi<sup>1</sup>, Rosalba Bavetta<sup>1</sup>, Floriana Bruno<sup>1</sup>, Serena Mistretta<sup>1</sup>, Stefania Tringali<sup>2</sup>, Roberta Fedele<sup>1</sup>, Luca Castagna<sup>2</sup> and Valentina Cappuzzo<sup>1</sup>

<sup>1</sup>UOS HLA – A.O.O.R. Villa Sofia-Cervello – Palermo, Italy; <sup>2</sup>Unità Trapianti Midollo Osseo – A.O.O.R. Villa Sofia-Cervello – Palermo, Italy;

## P66 | The impact of donor-specific antibodies presence on the outcome post-allogeneic hematopoietic stem cell transplantation: a survey from a single center

Sabrina Giammarco<sup>1</sup>, Patrizia Chiusolo<sup>2</sup>, Filippo Frioni<sup>1</sup>, Elisabetta Metafuni<sup>1</sup>, Maria Assunta Limongiello<sup>3</sup>, Eugenio Galli<sup>3</sup>, Federica Sorá<sup>2</sup>, Andrea Bacigalupo<sup>2</sup>, Elvira Poggi<sup>4</sup>, Mariano Antonio Feccia<sup>5</sup>, Annarita Manfreda<sup>5</sup> and Simona Sica<sup>2</sup>

<sup>1</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy; <sup>2</sup>Università Cattolica del Sacro Cuore, Italy; <sup>3</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; <sup>4</sup>CNR-IFT Roma San Camillo, Italy; <sup>5</sup>Centro Regionale Trapianti Lazio, Roma San Camillo, Italy

## P67 | Impact of HLA mismatches at the molecular level on the clinical evolution of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Francisco Javier Gil-Etayo<sup>1</sup>, Jairo Eduardo Niño-Ramírez<sup>2</sup>, Marta Fonseca<sup>1</sup>, Pilar Terradillos-Sánchez<sup>2</sup>, Isabel Jiménez Hernaz<sup>3</sup>, Ariadna Vicente Parra<sup>3</sup>, Ana Balanzategui<sup>3</sup>, Daniel Arroyo-Sánchez<sup>1</sup>, Beatriz García Martín<sup>1</sup>, Yasmín Roldán<sup>4</sup>, Francisco Boix<sup>5</sup>, Miguel Alcoceba<sup>6</sup>, Estefania Pérez<sup>1</sup>, Mónica Cabrero<sup>1</sup>

Almudena Navarro-Bailón<sup>1</sup>, Fermín Sánchez-Guijo<sup>1</sup>, Ramón García Sanz<sup>3</sup>, Lucía López-Corral<sup>1</sup> and Amalia Tejeda<sup>3</sup> <sup>1</sup>Department of Hematology, Hospital Universitario de Salamanca, Spain; <sup>2</sup>Department of Hematology, University Hospital of Salamanca, CIBERONC, Cancer Research Institute (CSIC-USAL University), Spain; <sup>3</sup>Laboratorio de HLA-Biología Molecular, Servicio de Hematología, Hospital Universitario de

Cancer Research Institute (CSIC-USAL University), Spain; <sup>3</sup>Laboratorio de HLA-Biología Molecular, Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain; <sup>4</sup>Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain; <sup>6</sup>Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain; <sup>6</sup>Hospital Universitario de Salamanca, Spain;





P68 | Inferior survival is observed among adult HSCT recipients having pre-transplant anti-HLA antibodies even though they are not directed against the donor

Antonio Milano<sup>1</sup>, Giuliana Lando<sup>2</sup>, Giulia Di Maggio<sup>2</sup>, Giorgia Cornacchini<sup>2</sup>, Giovanni Grillo<sup>2</sup>, Silvano Rossini<sup>2</sup> and Roberto Crocchiolo<sup>2</sup>

<sup>1</sup>Università Degli Studi di Milano Bicocca, Dipartimento di Medicina e Chirurgia, Italy; <sup>2</sup>ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

#### P69 | Management of ABO-incompatible HSCT: 2021-2023 data analysis

Chiara Sindici<sup>1</sup>, Donatella Londero<sup>1</sup>, Silvia Borgobello<sup>1</sup>, Elisa Cecchini<sup>1</sup>, Celeste Cervellin<sup>1</sup>, Ilaria Sandron<sup>1</sup> and Giovanni Barillari<sup>1</sup>

<sup>1</sup>Immunohematology and Blood Bank, ASUFC Udine, Italy

## P70 | Maternal uniparental disomy of chromosome 6 (upd(6) mat) in a patient affected by acute myelogenous leukemia awaiting HSC transplant

Franco Papola<sup>1</sup>, Alessandra Zoli<sup>2</sup>, Attilio Olivieri<sup>3</sup>, Raffaella Azzarone<sup>1</sup>, Olaida Valdez<sup>1</sup>, Maria Grazia Tupone<sup>1</sup>, Stefano Agolini<sup>2</sup>, Ilaria Scortechini<sup>3</sup>, Elia Trinchini<sup>1</sup>, Stefano Scipione<sup>1</sup>, Simona Scacchi<sup>1</sup>, Giovanni Rombolà<sup>4</sup> and Carla Cervelli<sup>1</sup>

<sup>1</sup>Regional Center for Immunohematology and Tissue Typing – ASL1 Abruzzo, L'Aquila, Italy; <sup>2</sup>HLA Laboratory – Marche University Hospital – Ancona, Italy; <sup>3</sup>Hematology Clinic – Marche University Hospital – Ancona, Italy; <sup>4</sup>Transplant Immunogenetics Parma University Hospital, Italy

### P71 | Post-Transplant Chimerism Monitoring – Real-Time qPCR or STR? Adriana Kaleva<sup>1</sup>, Elissaveta Naumova<sup>2</sup> and Tsvetelin Lukanov<sup>2</sup>

<sup>1</sup>Faculty of Biology, Sofia University "St. Kliment Ohridski", Sofia, Bulgaria; <sup>2</sup>Clinic of Clinical Immunology and Stem Cell Bank, University Hospital Alexandrovska, Sofia, Bulgaria

## P72 | Donor telomere length and telomerase reverse transcriptase gene polymorphism may affect the outcome of allogeneic hematopoietic stem cell transplantation in children – a preliminary study

## Marta Dratwa<sup>1</sup>, Barbara Wysoczanska<sup>1</sup>, Marek Ussowicz<sup>2</sup>, Blanka Rybka<sup>2</sup>, Renata Ryczan-Krawczyk<sup>2</sup>, Krzysztof Kalwak<sup>2</sup> and Katarzyna Bogunia-Kubik<sup>3</sup>

<sup>1</sup>Hirszfled Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland; <sup>2</sup>Department and Clinic of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wrocław Medical University, Poland; <sup>3</sup>Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

## P73 | Genetic predisposition to hematologic malignancies in patients undergoing allogeneic hematopoietic stem cell transplantation: case reports

Alice Brogi<sup>1</sup>, Sara Iozzi<sup>1</sup>, Beatrice Boschi<sup>1</sup>, Luisa Candita<sup>1</sup>, Giulia Carignani<sup>1</sup>, Giulio Capecchi<sup>2</sup>, Francesco Mannelli<sup>2</sup>, Paola Guglielmelli<sup>2</sup>, Chiara Nozzoli<sup>3</sup>, Simona Palchetti<sup>1</sup>, Mauro Leucio Mattei<sup>1</sup>, Martina Betti<sup>1</sup>, Elisabetta Pelo<sup>1</sup> and Irene Donnini<sup>3</sup>

<sup>1</sup>SOD Diagnostica Genetica, AOU Careggi, Florence, Italy; <sup>2</sup>CRIMM, Centro Ricerca e Innovazione Malattie Mieloproliferative, AOU Careggi, Firenze, Italy; <sup>3</sup>SOD Terapie Cellulari e Medicina Trasfusionale, AOU Careggi, Firenze, Italy;

## P74 | Standardization of evaluation of cytokine gene polymorphisms by next generation sequencing Selma Zenia D'Silva<sup>1</sup>, Manisha Tambe<sup>1</sup>, Shreya Kupekar<sup>1</sup> and Meenakshi Singh<sup>1</sup>

<sup>1</sup>ACTREC, TMC, India

## P75 | Improved haploidentical donor matching including low expression HLA loci in the immunogenetic analysis using Next-Generation Sequencing

Wiktoria Wypych<sup>1</sup>, Dominika Moskalik-Kierat<sup>1</sup>, Martyna Brzoza<sup>1</sup>, Anna Wasilewska<sup>1</sup>, Mateusz Mrozowski<sup>1</sup>, Agnieszka Jałbrzykowska<sup>1</sup>, Ewa Karakulska-Prystupiuk<sup>2</sup>, Piotr Kacprzyk<sup>2</sup>, Agnieszka Tomaszewska<sup>2</sup>, Grzegorz Basak<sup>2</sup> and Marcelina Grabowska<sup>1</sup>

<sup>1</sup>Laboratory of Immunogenetics UCML, University's Clinical Center of the Medical University of Warsaw, Poland; <sup>2</sup>Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland

#### P76 | Detection and monitoring of donor-specific antibodies in a haploidentical stem cell transplant recipient: a case report

## Małgorzata Kamińska<sup>1</sup>, Wanda Niepiekło-Miniewska<sup>1</sup>, Katarzyna Kościńska<sup>2</sup>, Anna Rybińska<sup>1</sup>, Monika Mordak-Domagała<sup>2</sup>, Jarosław Dybko<sup>2</sup> and Katarzyna Bogunia-Kubik<sup>1</sup>

<sup>1</sup>Laboratory of Tissue Immunology, Medical Centre, Institute of Immunology and Experimental Therapy PAS, Wroclaw, Poland; <sup>2</sup>Lower Silesian Oncology, Pulmonology and Hematology Center, Wroclaw, Poland;





P77 | Analysis of the significance of donor chimerism at +14 days after haploidentical hematopoietic stem cell transplantation

Zhulduz Zhanzakova<sup>1</sup>, Aida Turganbekova<sup>1</sup>, Dana Baimukasheva<sup>1</sup>, Zhazira Saduakas<sup>1</sup>, Didara Khamitova<sup>1</sup> and Sanya Abdrakhmanova<sup>1</sup>

<sup>1</sup>Research and Production Center of Transfusiology, Kazakhstan

P78 | Changes of the immunogenic profile of an acute myeloid leukemia relapsed patient with partial loss of heterozygosity in HLA genes after haploidentical transplantation of hematopoietic stem cells Anna Mazanova<sup>1</sup>, Anastasiia Maksymchuk<sup>1</sup>, Iryna Tubaltseva<sup>1</sup>, Nataliia Tsokolenko<sup>1</sup>, Olena Zemlianska<sup>1</sup>, Yana Muratova<sup>1</sup>, Anna Sheikina<sup>1</sup>, Yevhen Hrohul<sup>1</sup> and Natalia Olkhovych<sup>1</sup>

<sup>1</sup>Laboratory of Medical Genetics, National Specialized Children's Hospital "OHMATDYT" Ministry of Health of Ukraine, Ukraine

### P79 | Partial loss of heterozygosity in HLA genes in patient with relapsed acute lymphoblastic leukemia Yevhen Hrohul<sup>1</sup>, Anastasiia Maksymchuk<sup>1</sup>, Iryna Tubaltseva<sup>1</sup>, Nataliia Tsokolenko<sup>1</sup>, Olena Zemlianska<sup>1</sup>, Yana Muratova<sup>1</sup>, Anna Sheikina<sup>1</sup>, Anna Mazanova<sup>1</sup> and Natalia Olkhovych<sup>1</sup>

<sup>1</sup>Laboratory of Medical Genetics, National Specialized Children's Hospital "OHMATDYT" Ministry of Health of Ukraine, Ukraine

## P80 | Mismatched unrelated donors for hematopoietic stem cell transplantation in children with inborn errors of immunity: selection criteria and the Newcastle experience

**Jane Matthews<sup>1</sup>, Ruth Chisman<sup>1</sup>, Karen Moore<sup>1</sup>, Mary Slatter<sup>2</sup>, Su Han Lum<sup>2</sup> and Arash Akbarzad-Yousefi<sup>1</sup>** <sup>1</sup>H&I, NHS Blood and Transplant, Newcastle upon Tyne, United Kingdom; <sup>2</sup>Paediatric Immunology, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom

### **IMMUNOGENETICS IN ORGAN TRANSPLANTATION**

#### P81 | On the road to epitope matches and mismatches – with epiTOol

#### Claudia Lehmann<sup>1</sup>, Nils Lachmann<sup>2</sup>, Ilias Doxiadis<sup>1</sup> and Henry Loeffler-Wirth<sup>3</sup>

<sup>1</sup>Laboratory for Transplantation Immunology, University Hospital Leipzig, Germany; <sup>2</sup>Institute for transfusion Medicine, H & I Laboratory, Charité-Universitätsmedizin Berlin, Germany; <sup>3</sup>Interdisciplinary Centre for Bioinformatics, IZBI, Leipzig University, Germany

Following kidney transplantation although up to 40 epitope mismatches were present. In contrast, recipients with only nine EMM had produced antibodies towards the donor. Defining epitopes is helpful for understanding the humoral response but it is not a matter of numbers but a matter of quality and could be a useful tool for donor selection in the future.

## P82 | Clinical relevance of isolated preformed HLA-DP donor specific antibodies on the outcome of kidney transplantation

#### Alba Expósito Bey<sup>1</sup>, Beatriz Rodriguez Bayona<sup>1</sup> and María Francisca González Escribano<sup>1</sup>

<sup>1</sup>Servicio de Inmunología, Hospital Universitario Virgen del Rocío, Sevilla, Spain

## P83 | Interference of cold agglutinins and/or cryoglobulins in antibody diagnostics for kidney transplantation: a case study

### Steven Koetzier<sup>1</sup>, Joyce van Beers<sup>2</sup>, Jan Damoiseaux<sup>2</sup>, Christina Voorter<sup>1</sup> and Lotte Wieten<sup>1</sup>

<sup>1</sup>Department of Transplantation Immunology, Maastricht University Medical Center, Maastricht, Netherlands; <sup>2</sup>Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands

## P84 High levels of BCMA transcript expression prior to transplantation, increased plasmablast, lymphocyte B cell class-switched levels and viral loading are associated with early CMV reactivation in renal recipients

Marina Fernandez<sup>1</sup>, Rafael Alfaro<sup>1</sup>, Maria Jose Alegria-Marcos<sup>1</sup>, Jose Antonio Galian<sup>1</sup>, Helios Martinez-Banaclocha<sup>1</sup>, Carmen Botella<sup>1</sup>, Alfredo Minguela<sup>1</sup>, Maria Rosa Moya-Quiles<sup>1</sup>, Santiago Llorente<sup>1</sup>, Isabel Legaz<sup>2</sup> and Manuel Muro<sup>1</sup> <sup>1</sup>Immunology Service. University Clinical Hospital "Virgen de la Arrixaca". Murcia. Spain, Spain; <sup>2</sup>Department of Legal and Forensic Medicine. University of Murcia. Murcia, Spain

### P85 | Imlifidase for Kidney Transplantation of Highly Sensitized Patients with a Positive Crossmatch: The French Consensus Guidelines

Gwendaline Guidicelli<sup>1</sup>, Paolo Malvezzi<sup>2</sup>, Lucile Amrouche<sup>3</sup>, Dany Anglicheau<sup>3</sup>, Gilles Blancho<sup>4</sup>, Sophie Caillard<sup>5</sup>, Marine Freist<sup>6</sup>, Nassim Kamar<sup>7</sup>, Carmen Lefaucheur<sup>8</sup>, Christophe Mariat<sup>9</sup>, Alice Koenig<sup>10</sup>, Johan Noble<sup>2</sup>, Olivier Thaunat<sup>10</sup>, Antoine Thierry<sup>11</sup>, Jean-Luc Taupin<sup>8</sup>, Dominique Bertrand<sup>12</sup> and Lionel Couzi<sup>1</sup>

<sup>1</sup>Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; <sup>2</sup>Centre Hospitalier Universitaire de Grenoble, La Tronche, France; <sup>3</sup>Hôpital Necker-Enfants Malades, Paris, France; <sup>4</sup>Centre Hospitalier Universitaire (CHU) de Nantes, Nantes, France; <sup>5</sup>Hôpital Civil, Strasbourg, Strasbourg, France; <sup>6</sup>Centre Hospitalier Emile Roux, Le Puy-en-Velay, France; <sup>7</sup>Centre Hospitalier Universitaire de Toulouse, Toulouse, France; <sup>8</sup>Hôpital Saint-Louis, Paris, France; <sup>9</sup>Centre Hospitalier Universitaire de Saint-Étienne, Saint-Etienne, France; <sup>10</sup>Hospices Civils de Lyon, Lyon, France; <sup>11</sup>Centre Hospitalier Universitaire de Poitiers, Poitiers, France; <sup>12</sup>Centre Hospitalier Universitaire de Rouen, Rouen, France





P86 | Effect of peri-transplantation circumstances on the amelioration of cellular immunity following kidney transplantation

Lambros Vagiotas<sup>1</sup>, Georgios Lioulios<sup>1</sup>, Efstratios Kasimatis<sup>1</sup>, Aliki Xochelli<sup>1</sup>, Anna Boukla<sup>1</sup>, Georgia Chatzika<sup>1</sup>, Despoina Asouchidou<sup>1</sup>, Margarita Samali<sup>1</sup>, Nikolaos Antoniadis<sup>1</sup>, Georgios Tsoulfas<sup>1</sup>, Maria Stangou<sup>1</sup> and Asimina Fylaktou<sup>1</sup>

<sup>1</sup>Hippokration Hospital of Thessaloniki, Greece

### P87 | Detection of donor-derived cell-free DNA in sequential kidney transplanted patients Linnéa Pettersson<sup>1</sup>, Lukas Frischknecht<sup>2</sup>, Sofia Westerling<sup>1</sup>, Hamid Ramezanali<sup>1</sup>, Lukas Weidmann<sup>3</sup>,

### Kai Castrezana Lopez<sup>3</sup>, Thomas Schachtner<sup>3</sup> and Jakob Nilsson<sup>3</sup>

<sup>1</sup>Devyser AB, Sweden; <sup>2</sup>Department of Immunology, University Hospital Zurich (USZ), Switzerland; <sup>3</sup>Division of Nephrology, University Hospital Zurich (USZ), Switzerland;

## P88 | Role of HLA matching and donor specific antibody development in long-term survival, acute rejection and cardiac allograft vasculopathy

Dario Costa<sup>1</sup>, Antonietta Picascia<sup>1</sup>, Vincenzo Grimaldi<sup>1</sup>, Cristiano Amarelli<sup>2</sup>, Andrea Petraio<sup>2</sup>, Anna Levi<sup>1</sup>, Mario Di Donato<sup>1</sup>, Anna Virginia Adriana Pirozzi<sup>1</sup>, Carmela Fiorito<sup>1</sup>, Giusi Moccia<sup>1</sup>, Aurora Gallo<sup>1</sup>, Claudio Marra<sup>2</sup>, Marisa De Feo<sup>2</sup>, Francesco Cacciatore<sup>3</sup>, Ciro Maiello<sup>2</sup> and Claudio Napoli<sup>1</sup>

<sup>1</sup>UOC of Immunohematology, Transfusion Medicine and Transplant Immunology, University of Campania "L. Vanvitelli", Italy; <sup>2</sup>Cardiac Transplantation Unit, Department of Cardiac Surgery and Transplantation, Ospedali dei Colli, Italy; <sup>3</sup>Department of Translational Medicine Science, University of Naples Federico II, Italy

## P89 | Correlation between anti-angiotensin II receptor 1 and anti-endothelin type A receptor 1 in kidney transplanted pediatric patients

Antonio Giuseppe Bianculli<sup>1</sup>, Paola Giustiniani<sup>1</sup>, Annalisa Guagnano<sup>1</sup>, Andrea Di Luzio<sup>1</sup>, Francesca Besi<sup>1</sup>, Raffaella Labbadia<sup>2</sup>, Luca Antonucci<sup>2</sup>, Andrea Cappoli<sup>2</sup>, Isabella Guzzo<sup>2</sup> and Marco Andreani<sup>1</sup>

<sup>1</sup>Laboratorio di Immunogenetica dei Trapianti, Ospedale Pediatrico Bambino Gesù, Roma, Italy; <sup>2</sup>Nefrologia, Dialisi e Clinica del Trapianto di Rene, Ospedale Pediatrico Bambino Gesù, Roma, Italy

## P90 | Acute allograft dysfunction and glomerular microangiopathy in kidney transplant recipients in absence of donor specific anti-HLA antibodies: a case series

Nabigha Baki<sup>1</sup>, Ana Farfan Ruiz<sup>1</sup>, Tambi Jarmi<sup>1</sup> and Mohamed Elrefaei<sup>1</sup>

<sup>1</sup>Mayo Clinic, United States

P91 | Biomarkers of Innate Immunity and Immunological Susceptibility to Viral Infection in Patients with Alcoholic Cirrhosis

## Isabel Legaz<sup>1</sup>, Elena Navarro-Noguera<sup>1</sup>, Aurelia Collados-Ros<sup>1</sup>, Rosana Gonzalez-Lopez<sup>2</sup>, Jose Miguel Bolarin<sup>1</sup> and Manuel Muro<sup>2</sup>

<sup>1</sup>University of Murcia Department of Sociosanitary Sciences, Spain; <sup>2</sup>Immunology Service. Clinical University Hospital Virgen de la Arrixaca – IMIB – Murcia, Spain

### P92 | Non-HLA antibodies in highly sensitized recipients on the kidney waiting list Marija Burek Kamenaric<sup>1</sup>, Lucija Jukic<sup>2</sup>, Katarina Stingl Jankovic<sup>1</sup>, Marija Maskalan<sup>1</sup>, Zorana Grubic<sup>2</sup>, Natalija Martinez<sup>1</sup> and Renata Zunec<sup>2</sup>

<sup>1</sup>University Hospital Centre Zagreb, Croatia; <sup>2</sup>Tissue Typing Centre, University Hospital Centre Zagreb, Croatia

P93 | Deceased kidney donor virtual crossmatch introduction in north Italian transplant program (NITp) area Elena Longhi<sup>1</sup>, Loretta Crespiatico<sup>1</sup>, Viviana Sioli<sup>1</sup>, Vittoria Caporale<sup>1</sup>, Alessia Comino<sup>1</sup>, Francesca Drago<sup>1</sup>, Alejandro Espadas de Arias<sup>1</sup>, Miriam Ramondetta<sup>1</sup>, Augusto Tagliamacco<sup>1</sup>, Marco Guarene<sup>1</sup>, Denise Bertola<sup>1</sup>, Caterina Brambilla<sup>1</sup>, Nicoletta Cagni<sup>1</sup>, Sara Capogreco<sup>1</sup>, Ludovica Chidichimo<sup>1</sup>, Michela Grassi<sup>1</sup>, Annalisa Innocente<sup>1</sup>, Mario Macchiagodena<sup>1</sup>, Barbara Speringo<sup>1</sup>, Nemania Suvajac<sup>1</sup>, Mara Tivelli<sup>1</sup> and Tullia Maria De Feo<sup>1</sup> <sup>1</sup>Laboratorio Immunologia dei Trapianti, Fondazione IRCCS Ca<sup>'</sup> Granda Ospedale Maggiore Policlinico, Milano, Italy

## P94 | A personalized delisting strategy enables successful kidney transplantation in highly sensitized patients with preformed donor-specific anti-HLA antibodies.

Sandra García Jiménez<sup>1</sup>, Estela Paz-Artal<sup>1</sup>, Hernando Trujillo<sup>1</sup>, Natalia Polanco<sup>1</sup>, Maria J Castro<sup>1</sup>, Manuel J Del Rey<sup>1</sup>, Angel Alfocea<sup>1</sup>, Enrique Morales<sup>1</sup>, Esther Gonzalez<sup>1</sup>, Amado Andres<sup>1</sup> and Esther Mancebo<sup>1</sup> <sup>1</sup>Hospital Universitario 12 de Octubre, Spain





## P95 | Imlifidase desensitization in highly-HLA sensitized patients with positive Cross-Match: first experience in Parma

Silvia Giuliodori<sup>1</sup>, Madga Benecchi<sup>1</sup>, Pamela Berni<sup>1</sup>, Chiara Foroni<sup>1</sup>, Claudia Labate<sup>1</sup>, Roberta Merli<sup>1</sup>, Valentina Sgobba<sup>1</sup>, Stefania Bardini<sup>1</sup>, Francesca Lobascio<sup>1</sup>, Elisa Magni<sup>1</sup>, Joseph Manduca<sup>1</sup>, Jessica Parrotta<sup>1</sup>, Irene Pezzani<sup>1</sup>, Elena Russello<sup>1</sup>, Raffaele Troiano<sup>1</sup>, Umberto Maggiore<sup>2</sup> and Paola Zanelli<sup>1</sup>

<sup>1</sup>SSD Immunogenetics of Transplants, University Hospital of Parma, Italy; <sup>2</sup>SS Transplants, Nephrology Unit, Department of Medicine and Surgery, University of Parma, Italy

### P96 | Case report: simultaneous combined liver-kidney transplant. Focus on immunological assessment Paola Zanelli<sup>1</sup>, Silvia Giuliodori<sup>1</sup>, Giorgia Comai<sup>2</sup>, Matteo Ravaioli<sup>3</sup>, Irene Pezzani<sup>1</sup>, Giovanni Rombolà<sup>1</sup> and Gaetano La Manna<sup>2</sup>

<sup>1</sup>Immunogenetics, Parma University Hospital, Italy; <sup>2</sup>Nephrol, Dial and Kidney Transpl, IRCCS-AOU Bologna; Dept Medical and Surgical Sciences, University of Bologna, Italy; <sup>3</sup>Dept Medical and Surgical Sciences, University of Bologna; Hepato-biliary Surgery and Transpl, IRCCS AOU Bologna, Italy

### P97 | Desensitization-Resistant Eplet-Specific HLA Antibodies

Sebahat Usta Akgul<sup>1</sup>, Umit Aslanhan<sup>1</sup>, Reza Kazamzadeh<sup>1</sup>, Yaren Alan<sup>1</sup>, Erol Demir<sup>1</sup>, Deniz Ece Sallı<sup>1</sup>, Amir Tabatabaei<sup>1</sup>, Talin Catalbasyan<sup>1</sup>, Demir Kaan Demir<sup>1</sup>, Mehmet Kanbay<sup>2</sup>, Burak Kocak<sup>3</sup> and Caner Susal<sup>1</sup>

<sup>1</sup>Transplant Immunology Research Center of Excellence, Koç University Hospital, Turkey; <sup>2</sup>Department of Medicine, Division of Nephrology, Koç University Hospital, Turkey; <sup>3</sup>Münci Kalayoglu Organ Transplantation Center, Koç University Hospital, Turkey

## P98 | Differences of the subpopulations of T-lymphocytes between long-term and recent kidney transplant recipients

## Evangelos Memmos<sup>1</sup>, Georgios Lioulios<sup>2</sup>, Efstratios Kasimatis<sup>3</sup>, Aliki Xochelli<sup>4</sup>, Lambros Vagiotas<sup>5</sup>, Vasiliki Nikolaidou<sup>4</sup>, Nikolaos Antoniadis<sup>5</sup>, Georgios Tsoulfas<sup>5</sup>, Maria Stangou<sup>3</sup> and Asimina Fylaktou<sup>4</sup>

<sup>1</sup>Nephrology Department, "Papageorgiou" General Hospital, Thessaloniki, Greece; <sup>2</sup>Department of Nephrology, 424 General Military Hospital of Thessaloniki, Greece; <sup>3</sup>First Nephrology Department, A.U.Th., Hippocration General Hospital, Thessaloniki, Greece; <sup>4</sup>National Peripheral Histocompatibility Center, Immunology Department, Hippokration General Hospital, Thessaloniki, Greece; <sup>5</sup>Transplantation Department, A.U.Th., Hippocration General Hospital, Thessaloniki, Greece

### P99 | The reduction of T and B regulatory lymphocytes in long-term kidney transplant recipients Evangelos Memmos<sup>1</sup>, Efstratios Kasimatis<sup>2</sup>, Georgios Lioulios<sup>3</sup>, Aliki Xochelli<sup>4</sup>, Lambros Vagiotas<sup>5</sup>, Vasiliki Nikolaidou<sup>4</sup>, Nikolaos Antoniadis<sup>5</sup>, Georgios Tsoulfas<sup>5</sup>, Maria Stangou<sup>2</sup> and Asimina Fylaktou<sup>4</sup>

<sup>1</sup>Nephrology Department, "Papageorgiou" General Hospital, Thessaloniki, Greece; <sup>2</sup>First Nephrology Department, A.U.Th., Hippocration General Hospital, Thessaloniki, Greece; <sup>3</sup>Department of Nephrology, 424 General Military Hospital of Thessaloniki, Greece; <sup>4</sup>National Peripheral Histocompatibility Center, Immunology Department, Hippokration General Hospital, Thessaloniki, Greece; <sup>5</sup>Transplantation Department, A.U.Th., Hippocration General Hospital, Thessaloniki, Greece

## P100 | Pre-transplant flow cytometric crossmatch in patients undergoing Rituximab treatment: employment of Pronase and anti-CD20

Mario Macchiagodena<sup>1</sup>, Barbara Speringo<sup>1</sup>, Miriam Ramondetta<sup>1</sup>, Viviana Sioli<sup>1</sup>, Augusto Tagliamacco<sup>1</sup>, Alessia Comino<sup>1</sup>, Caterina Brambilla<sup>1</sup>, Nicoletta Cagni<sup>1</sup>, Annalisa Innocente<sup>1</sup>, Sara Capogreco<sup>1</sup>, Loretta Crespiatico<sup>1</sup> and Elena Longhi<sup>1</sup>

<sup>1</sup>Laboratorio Immunologia dei Trapianti, Fondazione IRCCS Ca<sup>′</sup> Granda Ospedale Maggiore Policlinico, Milano, Italy

### P101 | Deciphering HLA Antibody Reactivity Patterns: A Cluster-Based Analysis of SAB Assay Data Luís Ramalhete<sup>1</sup>, Cristiana Teixeira<sup>2</sup>, Maria Isabel Silva<sup>2</sup> and Ruben Araujo<sup>3</sup>

<sup>1</sup>Centro Sangue e Transplantação de Lisboa, Nova Medical School, Portugal

<sup>2</sup>Centro Sangue e Transplantação de Lisboa, Portugal; <sup>3</sup>Nova Medical School, Portugal

### P102 | Can Molecular HLA Mismatch Scores Predict Antibody-Mediated Rejection in Desensitized Kidney Transplant Recipients?

### Sebahat Usta Akgul<sup>1</sup>, Yaren Alan<sup>1</sup>, Erol Demir<sup>1</sup>, Neslihan Celik<sup>1</sup>, Umit Aslanhan<sup>1</sup>, Talin Catalbasyan<sup>1</sup>, Demir Kaan Demir<sup>1</sup>, Deniz Ece Salli<sup>1</sup>, Mehmet Kanbay<sup>2</sup>, Dilek Ertoy Baydar<sup>3</sup>, Caner Susal<sup>1</sup> and Burak Kocak<sup>4</sup> <sup>1</sup>Transplant Immunology Research Center of Excellence, Koç University Hospital, Turkey; <sup>2</sup>Department of Medicine, Division of Nephrology, Koc University

School of Medicine, Turkey; <sup>3</sup>Department of Pathology, Koç University School of Medicine, Turkey; <sup>4</sup>Department of Organ Transplantation, Koç University Hospital, Turkey





#### P103 | Clinical utility of 1:16 serum dilution as a predictor of response to therapeutic plasma exchange for HLA antibody-mediated rejection treatment and overall survival in lung transplant recipients: A two center study Mohamed Elrefaei<sup>1</sup>, Tathagat Narula<sup>1</sup>, Francisco Alvarez<sup>1</sup>, Elizabeth Godbey<sup>1</sup>, Gerard Criner<sup>2</sup>, Francis Cordova<sup>2</sup>, Norihisa Shigemura<sup>3</sup>, Yoshiya Toyoda<sup>3</sup> and Olga Timofeeva<sup>4</sup>

<sup>1</sup>Mayo Clinic, United States; <sup>2</sup>Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, United States; <sup>3</sup>Department of Surgery, Lewis Katz School of Medicine, Temple University, United States; <sup>4</sup>Department of Laboratory Medicine and Pathology, MedStar Georgetown University, United States

## P104 | Characterization of sHLA-AlexaFluor647-conjugates for accurate determination of serum HLA antibody concentration and affinity

## Matthias Reist<sup>1</sup>, Rico Buchli<sup>2</sup>, Sean R. A. Devenish<sup>3</sup>, Dominik Meinel<sup>4</sup>, Sebastiaan Heidt<sup>5</sup>, Canthia S.M. Kramer<sup>5</sup>, Suzanne Bezstarosti<sup>5</sup>, Rosa G.M. Lammerts<sup>6</sup>, Stefan Schaub<sup>7</sup> and Gideon Hönger<sup>1</sup>

<sup>1</sup>Molecular Immune Regulation, Department of Biomedicine, University of Basel, Basel, Switzerland; <sup>2</sup>PureProtein LLC, Department of Research and Development, Oklahoma City, Oklahoma, United States; <sup>3</sup>Fluidic Analytics, The Paddocks Business Centre, Cherry Hinton Rd, Cambridge, United Kingdom; <sup>4</sup>University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences Muttenz, Muttenz, Switzerland; <sup>5</sup>Department of Immunology, Leiden University Medical Center, Leiden, Netherlands; <sup>6</sup>Transplantation Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; <sup>7</sup>Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland

#### P105 | High Levels of Complement-Binding Donor-Specific Anti-HLA Antibodies: Are They Always Pathogenic? Katrin Hacke<sup>1</sup>, Firas Marayati<sup>2</sup>, Sami Alasfar<sup>2</sup>, Hasan A. Khamash<sup>2</sup>, Lavanya Kodali<sup>2</sup>, Pooja Budhiraja<sup>2</sup>, Girish K. Mour<sup>2</sup>, Bassam G. Abu Jawdeh<sup>2</sup> and Andrés Jaramillo<sup>1</sup>

<sup>1</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, Arizona, United States; <sup>2</sup>Department of Medicine, Mayo Clinic, Phoenix, Arizona, United States

## P106 | Effect of HLA-B -21 dimorphism on cellular response after COVID-19 vaccination in patients with renal disorders

Wanda Niepiekło-Miniewska<sup>1</sup>, Małgorzata Kamińska<sup>1</sup>, Katarzyna Kościelska-Kasprzak<sup>2</sup>, Dorota Bartoszek<sup>2</sup>, Marcelina Żabińska<sup>2</sup>, Dorota Kamińska<sup>2</sup>, Magdalena Krajewska<sup>2</sup> and Katarzyna Bogunia-Kubik<sup>1</sup> <sup>1</sup>Laboratory of Tissue Immunology, Medical Centre, Institute of Immunology and Experimental Therapy PAS, Wroclaw, Poland; <sup>2</sup>Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland

## P107 | Could donor-derived cell-free DNA level be considered a potential biomarker of subclinical graft rejection or early organ damage in kidney transplant recipients?

Marina Fernandez-Gonzalez<sup>1</sup>, Victor Jimenez-Coll<sup>1</sup>, Carmen Botella<sup>1</sup>, Rosana Gonzalez-Lopez<sup>1</sup>, Maria Jose Alegria-Marcos<sup>1</sup>, Carlos Sanchez-Rodriguez<sup>1</sup>, Maria Rosa Moya-Quiles<sup>1</sup>, Jose Antonio Galian<sup>1</sup>, Santiago Llorente-Viñas<sup>1</sup>, Isabel Saura-Luján<sup>1</sup>, Francisco Morales-Caravaca<sup>1</sup>, Gloria Martinez-Gomez<sup>1</sup> and Manuel Muro<sup>1</sup>

<sup>1</sup>Hospital Clinico Universitario Virgen de la Arrixaca (Murcia), Spain

## P108 | A critical retrospective analysis of Flow Cytometry Crossmatch in the emergency context in order to optimize the available resources

Cláudia Silva<sup>1</sup>, Paula Aires<sup>1</sup>, Pedro Ramoa<sup>1</sup>, Paula Santo<sup>1</sup> and Paula Xavier<sup>1</sup> <sup>1</sup>Instituto Português do Sangue e Transplantação, IP, Portugal

## P109 | Positive crossmatch in ABO-incompatible neonatal heart transplant due to transplacental transfer of maternal HLA antibodies

Cristiana Caorsi<sup>1</sup>, Gabriele Maria Togliatto<sup>1</sup>, Claudia Maria Rosso<sup>1</sup>, Sara Tontoni<sup>2</sup>, Rossella Chidichimo<sup>2</sup>, Enrico Aidala<sup>3</sup>, Carlo Pace Napoleone<sup>3</sup> and Silvia Deaglio<sup>2</sup>

<sup>1</sup>Immunogenetics and Transplant Biology Service, Città Della Salute e Della Scienza University Hospital, Turin, Italy; <sup>2</sup>Immunogenetics and Transplant Biology Service, AOU Città della Salute e della Scienza, Turin, Italy; <sup>3</sup>Pediatric and Congenital Cardiac Surgery Department, Regina Margherita Children's Hospital, Turin, Italy

## P110 | Comparison of results of crossmatch tests from peripheral blood cells with crossmatch tests from secondary lymphoid organs cells in kidney transplantation

Aggeliki Vittoraki<sup>1</sup>, Georgios Lioulios<sup>2</sup>, Alexandra Siorenta<sup>1</sup>, Margarita Samali<sup>3</sup>, Chrysanthi Tsirligkani<sup>1</sup>, Aliki Xochelli<sup>3</sup>, Aikaterini Anastasiou<sup>3</sup>, Vasiliki Nikolaidou<sup>3</sup>, Athina Aikaterini Nikolaou<sup>1</sup>, Georgios Paterakis<sup>1</sup> and Asimina Fylaktou<sup>3</sup>

<sup>1</sup>Immunology Department & National Tissue Typing Center, General Hospital of Athens "G. Gennimatas", Athens, Greece; <sup>2</sup>Department of Nephrology, 424 General Military Hospital of Thessaloniki, Greece; <sup>3</sup>National Peripheral Histocompatibility Center, Immunology Department, Hippokration General Hospital, Thessaloniki, Greece;





#### P111 | Donor derived cell-free DNA: clinical utility in surveillance strategy for heart transplant Elvira Poggi<sup>1</sup>, Vincenzo Dinallo<sup>2</sup>, Sabina Maria Bruno<sup>2</sup>, Silvia Sinopoli<sup>2</sup>, Giada Distefano<sup>3</sup>, Fabio Sbaraglia<sup>3</sup>, Giulio Cacioli<sup>3</sup>, Federico Ranocchi<sup>3</sup>, Rachele Adorisio<sup>4</sup>, Antonio Amodeo<sup>5</sup> and Mariano Antonio Feccia<sup>6</sup>

<sup>1</sup>CNR-IFT Roma San Camillo, Centro Regionale Trapianti Lazio-AO San Camillo Forlanini, Italy; <sup>2</sup>Centro Regionale Trapianti Lazio-AO San Camillo Forlanini, Italy; <sup>3</sup>UOC Cardiochirurgia e Trapianto Cuore-AO San Camillo Forlanini, Italy; <sup>4</sup>UOC Cardiochirurgia e Trapianto Cardiaco Pediatrico-Osp Pediatrico Bambino Gesù, Italy; <sup>5</sup>UOC Cardiochirurgia e TrapiantoCcardiaco Pediatrico-Osp Pediatrico Bambino Gesù, Univ Cattolica Sacro Cuore Roma, Italy; <sup>6</sup>UOC Cardiochirurgia e Trapianto Cuore-AO San Camillo Forlanini , Centro Regionale Trapianti Lazio, Italy

#### P112 | Diagnosis and treatment of humoral rejection in heart-transplant patients: single center experience Elvira Poggi<sup>1</sup>, Annarita Manfreda<sup>2</sup>, Silvia Sinopoli<sup>2</sup>, Ivan Gabrielli<sup>2</sup>, Vincenzo Dinallo<sup>2</sup>, Simona Caporali<sup>2</sup>, Sabina Maria Bruno<sup>2</sup>, Federico Ranocchi<sup>3</sup>, Giada Distefano<sup>3</sup>, Fabio Sbaraglia<sup>3</sup> and Mariano Antonio Feccia<sup>3</sup>

<sup>1</sup>CNR-IFT Roma San Camillo, Centro Regionale Trapianti Lazio-AO San Camillo Forlanini, Italy; <sup>2</sup>Centro Regionale Trapianti Lazio-AO San Camillo Forlanini, Italy; <sup>3</sup>UOC Cardiochirurgia e Trapianto Cuore-AO San Camillo Forlanini , Centro Regionale Trapianti Lazio, Italy

#### P113 | Correlation between DSA and kidney transplant prognosis

Hyun-Ji Lee<sup>1</sup>, Shingyeop Hwang<sup>2</sup>, Hanbin Jeong<sup>2</sup>, Soohyun Lee<sup>2</sup>, Junhyun Gu<sup>2</sup> and Kyunghwa Shin<sup>2</sup> <sup>1</sup>Pusan National University, Yangsan Hospital, South Korea; <sup>2</sup>Pusan National University, South Korea

## P114 | Luminex single antigen assay on 1:10 diluted serum predicts the drop in anti-HLA antibodies before desensitization

**Dominique Bertrand<sup>1</sup>, Charlotte Laurent<sup>1</sup>, Fabienne Farce<sup>2</sup> and Rangolie Kaveri<sup>2</sup>** <sup>1</sup>CHU de Rouen, France; <sup>2</sup>EFS HFNO, France

P115 | A comprehensive comparative assessment of mean fluorescence intensity of Luminex single antigen bead tests between laboratories and commercial platforms; a report from the Italian histocompatibility network Antonina Piazza<sup>1</sup>, Giovanni Rombolà<sup>2</sup>, Dario Ciappi<sup>3</sup>, Maria Chiara de Stefano<sup>4</sup>, Umberto Maggiore<sup>5</sup>, Sara Iozzi<sup>6</sup>, Andrea Ricci<sup>4</sup>, Franco Papola<sup>7</sup> and Massimo Cardillo<sup>4</sup>

<sup>1</sup>EPT Committee, Italian National Transplant Centre, Istituto Superiore di Sanità, Rome, Italy; <sup>2</sup>Immunogenetics, Parma University Hospital, Italy; <sup>3</sup>University of Florence, Italy; <sup>4</sup>Italian National Transplant Centre, Istituto Superiore di Sanità, Rome, Italy; <sup>5</sup>Kidney-Pancreas Transplant Unit, Nephrology, Medicine and Surgery Dept,, University of Parma, Italy; <sup>6</sup>Diagnostic Genetics, Careggi University Hospital, Florence, Italy; <sup>7</sup>Immunohematology and Tissue Typing Regional Centre, L'Aquila – AIBT President, Italy;

P116 | Exploring false positive reactions in Anti-HLA antibody identification via Single Antigen testing Besma Sifi<sup>1</sup>, Fethi Meçabih<sup>2</sup> and Nabila Attal<sup>2</sup>

<sup>1</sup>Institut Pasteur d'Algérie, Algeria; <sup>2</sup>Institut Pasteur d'Algérie; Faculté de Pharmacie d'Algérie, Algeria

**P117** | Urine Biomarker CXCL10 Bead-Based Detection Assay for Monitoring Clinical Transplant Rejection Julie Nguyen<sup>1</sup>, Michael Trinh<sup>1</sup>, Elizeh Hasan<sup>1</sup>, Chien-Yu Chen<sup>1</sup>, Rui Pei<sup>1</sup> and Dave Lowe<sup>1</sup> <sup>1</sup>Thermo Fisher Scientific, United States

## P118 | Evaluation of serotype representation in different Luminex single antigen kits regarding the serotype frequencies in 2,021 deceased donors

Renato de Marco<sup>1</sup>, Alberto Cardoso Martins Lima<sup>1</sup>, João Henrique Campos<sup>1</sup> and Maria Gerbase-DeLima<sup>1</sup> <sup>1</sup>Immunogenetics Institute – IGEN, Associação Fundo de Incentivo à Pesquisa, São Paulo, SP, Brazil

## P119 | Strategy for delisting prohibited HLA antigens to increase the possibilities of kidney transplantation of hypersensitized patients

Juanfran Luchoro-Cerda<sup>1</sup>, José Luis Caro<sup>1</sup>, David Cucchiari<sup>1</sup>, Juan Torres<sup>1</sup>, Esther Mancebo<sup>2</sup>, María José Pérez-Saez<sup>3</sup>, Marta Crespo<sup>3</sup>, Amado Andrés-Belmonte<sup>2</sup>, Francesc Moreso<sup>4</sup>, Oriol Bestard<sup>4</sup>, Fritz Diekmann<sup>1</sup> and Eduard Palou<sup>1</sup>

<sup>1</sup>Hospital Clínic de Barcelona, Spain; <sup>2</sup>Hospital Universitario 12 de Octubre, Spain; <sup>3</sup>Hospital del Mar, Spain; <sup>4</sup>Hospital Universitari Vall d'Hebron, Spain

#### P120 | Immunogenetic Profiling in Living Donor Kidney Transplantation: Insights from DSAs and Pronase-Treated Flow Cytometry Crossmatch

#### Luís Ramalhete<sup>1</sup>, Ana Teixeira<sup>2</sup>, Cristiana Teixeira<sup>2</sup>, Maria Isabel Silva<sup>2</sup>, Paula Almeida<sup>2</sup>, Alice Lima<sup>2</sup> and Ruben Araujo<sup>3</sup>

<sup>1</sup>Centro Sangue e Transplantação de Lisboa, Nova Medical School, Portugal; <sup>2</sup>Centro Sangue e Transplantação de Lisboa, Transplantação, Portugal; <sup>3</sup>Nova Medical School, Portugal





### P121 | Optimizing Kidney Re-transplantation Outcomes: Validation of a Highly Sensitive Assay for Monitoring of Donor-Derived Cell-Free DNA

**Sofia Westerling<sup>1</sup>, Natasa Sikanic<sup>1</sup>, Venkat Talla<sup>1</sup> and Linnéa Pettersson<sup>1</sup>** <sup>1</sup>Devyser, Sweden;

P122 | HLA-DQA1\*03:02-DQB1\*03:03 is the dominant immunogenic heterodimer for post-transplant HLA-DQ *de novo* DSA development in a cohort of Chinese kidney transplant patients Xiangjun Liu<sup>1</sup>, Zhaoru Huang<sup>2</sup> and Wenjun Shang<sup>2</sup>

<sup>1</sup>BFR Diagnostics, China; <sup>2</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

P123 | Cross-platform optimization of (d)dPCR assays intended for donor-derived cell-free DNA monitoring Bram Luiken<sup>1</sup>, Lara van der Klugt<sup>1</sup>, Bo Rood<sup>1</sup>, Bart Valkenburg<sup>1</sup>, Freek Manders<sup>1</sup>, Eleni Draina<sup>1</sup> and Sake van Wageningen<sup>1</sup>

<sup>1</sup>GenDx, Netherlands

P124 | Playing Hide and Seek with HLA-DRB3/4/5 Data in Kidney Transplantation Reports in Argentina Manuel Quirno Costa<sup>1</sup>

<sup>1</sup>Hospital General de Agudos "Carlos G. Durand", Argentina

P125 | Analysis of the influence of IgM on the results of CDC-XM in patients with chronic kidney disease Aida Turganbekova<sup>1</sup>, Didara Khamitova<sup>1</sup>, Zhulduz Zhanzakova<sup>1</sup>, Dana Baimukasheva<sup>1</sup>, Zhazira Saduakas<sup>1</sup> and Sanya Abdrakhmanova<sup>1</sup>

<sup>1</sup>Republican Scientific and Production Center for Transfusiology, Astana, Kazakhstan

#### P126 | Kinetics of donor-derived cell-free DNA in the early kidney post-transplantation phase Mauro Leucio Mattei<sup>1</sup>, Serena Rossinelli<sup>1</sup>, Marilù Bartiromo<sup>2</sup>, Martina Betti<sup>1</sup>, Sara Iozzi<sup>1</sup>, Eleonora Pizzo<sup>2</sup>,

**Glenda Cancila<sup>2</sup>, Alice Brogi<sup>1</sup>, Elisabetta Pelo<sup>1</sup>, Lino Cirami<sup>2</sup>, Sergio Serni<sup>3</sup> and Simona Palchetti<sup>1</sup>** <sup>1</sup>SODc Diagnostica Genetica AOU Careggi, Florence, Italy; <sup>2</sup>SOD Nefrologia Dialisi e Trapianto AOU Careggi, Florence, Italy; <sup>3</sup>Dept. of Minimally Invasive, Robotic Urologic Surgery and Kidney Transplantation University of Florence, Italy

## P127 | HLA mismatch and circulating donor-specific antibodies predict long term graft loss after kidney transplantation: a retrospective study from Campania region, Italy

**Mariagrazia Strozziero<sup>1</sup>, Dario Costa<sup>1</sup>, Giuditta Benincasa<sup>1</sup>, Vincenzo Grimaldi<sup>1</sup>, Paride De Rosa<sup>2</sup>, Giovanni Valeriani<sup>2</sup>, Michele Santangelo<sup>3</sup>, Rosa Carrano<sup>3</sup>, Sara Pacilio<sup>4</sup>, Francesco Cacciatore<sup>4</sup> and Claudio Napoli<sup>1</sup>** <sup>1</sup>UOC of Immunohematology, Transfusion Medicine and Transplant Immunology, University of Campania "L. Vanvitelli", Italy; <sup>2</sup>General Surgery and Transplantation Unit, "San Giovanni di Dio e Ruggi D'Aragona," University Hospital, Italy; <sup>3</sup>Department of Public Health, Section of Nephrology, University of Naples "Federico II", Italy; <sup>4</sup>Department of Translational Medical Sciences, University of Naples "Federico II", Italy

## P128 | Performance of Devyser's NGS-based Assay for Monitoring donor-derived cell-free DNA in Kidney Allografted Patients

Annette Plesner<sup>1</sup>, Soeren Schwartz Soerensen<sup>1</sup> and Helle Bruunsgaard<sup>1</sup> <sup>1</sup>Copenhagen University Hospital, Rigshospitalet, Denmark

P129 | Effect of serum dilution in the patient with antibody-mediated rejection undergoing therapeutic plasma exchange

Olaida Valdez<sup>1</sup>, Maria Grazia Tupone<sup>1</sup>, Cervelli Carla<sup>1</sup>, Alessandra Panarese<sup>2</sup>, Anna Rughetti<sup>3</sup>, Carla Battistoni<sup>1</sup>, Daniela Pulcinelli<sup>1</sup>, Vittoriano Torrelli<sup>1</sup>, Ivana Abruscio<sup>1</sup> and Franco Papola<sup>1</sup>

<sup>1</sup>Regional Center for Immunohematology and Tissue Typing – ASL1 Abruzzo, L'Aquila, Italy; <sup>2</sup>Organ Transplant Center – L'Aquila, Italy; <sup>3</sup>Immunohematology and Transfusion Medicine Service – ASL1 Abruzzo, L'Aquila, Italy

## P130 | The interpretation of the anti-HLA-A3 appearance after treatment with anti-thymocyte globulin Jelena Dmitrovic<sup>1</sup>, Tatjana Dukic<sup>1</sup> and Zorana Andric<sup>1</sup>

<sup>1</sup>Tissue Typing Department, Blood Transfusion Institute of Serbia, Belgrade, Serbia

## P131 | CDC vs Luminex in HLA class I antibody detection – 12 years' experience in Tissue Typing Laboratory, Rijeka

## Tajana Crnić Marčetić<sup>1</sup>, Nataša Katalinić<sup>2</sup>, Aida Mujić Franić<sup>1</sup>, Helena Kurtović<sup>1</sup>, Ines Šimac Sušanj<sup>1</sup>, Hrvoje Rimac<sup>1</sup> and Sanja Balen<sup>2</sup>

<sup>1</sup>Tissue Typing Laboratory, Clinical Hospital Center Rijeka, Croatia; <sup>2</sup>Tissue Typing Laboratory, CHC Rijeka; Department of Clinical Laboratory Diagnostics, Medical Faculty Rijeka, Croatia





## P132 | Optimizing a protocol for diluting patient serum with EDTA as a pre-treatment step toward suppressing the prozone effect in the detection of anti-HLA antibodies

#### Daniel Iguasnia Portilla<sup>1</sup>, Ricardo Cuesta<sup>2</sup>, Rocío Navarro<sup>3</sup>, Manuel Rodríguez<sup>3</sup>, Luisa Mas<sup>3</sup>, Rafaela Sánchez<sup>3</sup>, Isabel Terrón<sup>3</sup>, Rosa Granell<sup>3</sup>, Estefanía Solaz<sup>3</sup>, Dolores Planelles<sup>3</sup>, Luis-Hidalgo Mar<sup>3</sup>, Castro Emma<sup>3</sup>, Luis Larrea<sup>3</sup>, Cristina Arbona<sup>3</sup> and Francisco Boix<sup>3</sup>

<sup>1</sup>Unit of Clinical Immunology and Genetics. University Hospital Complex of Cáceres., Spain; <sup>2</sup>Immunology Department. University Hospital La Paz. Community of Madrid. Madrid. Spain, Spain; <sup>3</sup>Histocompatibility laboratory. Processing Department. Transfusion Centre of the Valencian Community, Valencia, Spain

## P133 | Comparison of Two Single Antigen Bead Assays for Detection of Anti-HLA Antibodies and assessment of their complement-binding capacity

Asimina Fylaktou<sup>1</sup>, Georgios Lioulios<sup>2</sup>, Georgios Petasis<sup>1</sup>, Marianthi Papachristou<sup>1</sup>, Margarita Samali<sup>1</sup>, Artemis Maria Iosifidou<sup>3</sup>, Myrto Aikaterini Iosifidou<sup>3</sup>, Aikaterini Anastasiou<sup>1</sup>, Maria Stangou<sup>4</sup> and Ioannis Theodorou<sup>5</sup>

<sup>1</sup>National Peripheral Histocompatibility Center – Immunology Department, Hippokration General Hospital, Thessaloniki, Greece; <sup>2</sup>Department of Nephrology, 424 Military Hospital, Thessaloniki, Greece; <sup>3</sup>School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; <sup>4</sup>Department of Nephrology, Hippokration Hospital, Thessaloniki, Greece; <sup>5</sup>Laboratoire d'Immunologie, Hôpital Robert Debré, Paris, France

P134 | First experiences with detection of dd-cfDNA in heart transplant patients in North Macedonia Meri Kirijas<sup>1</sup>, Marija Gjerakarovska Radovikj<sup>2</sup>, Kristina Stamatovska<sup>1</sup>, Boban Dobrevski<sup>1</sup>, Gorjan Milanovski<sup>1</sup>, Teodora Brnjarchevska Blazevska<sup>1</sup>, Tamara Savevska<sup>1</sup> and Aleksandar Petlichkovski<sup>1</sup>

<sup>1</sup>Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Macedonia; <sup>2</sup>University Clinic for Cardiac Surgery, Skopje, Macedonia

#### P135 | MicroRNAs as Potential Graft Rejection or Tolerance Biomarkers and Their Dilemma in Clinical Routines Behaving like Devilish, Angelic, or Frightening Elements

Marina Fernandez-Gonzalez<sup>1</sup>, Maria Jose Alegria-Marcos<sup>1</sup>, Santiago Llorente<sup>1</sup>, Rosana Gonzalez-Lopez<sup>1</sup>, Jose Antonio Galian<sup>1</sup>, Helios Martinez-Banaclocha<sup>1</sup>, Carmen Botella<sup>1</sup>, Maria Rosa Moya-Quiles<sup>1</sup>, Alfredo Minguela<sup>1</sup>, Isabel Legaz<sup>1</sup> and Manuel Muro<sup>1</sup>

<sup>1</sup>Immunology Service, University Clinical Hospital "Virgen de la Arrixaca", IMIB, Murcia, Spain;

## P136 | Validation of the Flow cytometry crossmatch technique with the BD FACSLyric and calculation of new cut-off values

Cláudia Silva<sup>1</sup>, Paula Aires<sup>1</sup>, Paula Santo<sup>1</sup>, Pedro Ramoa<sup>1</sup> and Paula Xavier<sup>1</sup> <sup>1</sup>Instituto Português do Sangue e Transplantação, IP, Portugal

P137 | Challenges in Immunological evaluation of Four Sensitized Patients

Mahendra Mishra<sup>1</sup> and Aarti Nagpal<sup>1</sup>

<sup>1</sup>Pathkind Diagnostics Pvt. Ltd. National Reference Laboratory, India

#### P138 | Analysis of HLA-A, -B and -DRB1 genes in living donor kidney transplantation in Montenegro Marko Grubač<sup>1</sup>, Marina Ratković<sup>2</sup> and Renata Zunec<sup>3</sup>

<sup>1</sup>Laboratory for HLA Diagnostics, Institute for Blood Donation of Montenegro, 81000 Podgorica, Montenegro; <sup>2</sup>Private Medical Center "Luča", 81000 Podgorica, Montenegro; <sup>3</sup>Tissue Typing Center, University Hospital Center Zagreb, 10 000 Zagreb, Croatia

#### P139 | HLA-antibodies in solid organ transplantation: Eplet analysis of a paired kidney cohort

Anna-Lena Semmler<sup>1</sup>, Nigar Fattahova<sup>1</sup>, Michael Weyrich<sup>2</sup>, Thimoteus Speer<sup>2</sup> and Christian Seidl<sup>1</sup>

<sup>1</sup>Institute for Transfusion Medicine and Immunohematology, German Red Cross Blood Service Baden-Württemberg, Hessen, Germany; <sup>2</sup>Department of Internal Medicine 4, Nephrology, Goethe University Frankfurt, Germany

#### **IMMUNOTHERAPY, GENE THERAPY & NK CELLS**

#### P140 | NK Cell-Based Adoptive Immunotherapy for Controlling HLA class II Antibody-Mediated Rejection in Transplantation

#### Carolt Arana<sup>1</sup>, Ainhoa Garcia-Busquets<sup>2</sup>, Sergi Betriu<sup>3</sup>, Eduard Palou<sup>3</sup>, Fritz Diekmann<sup>1</sup> and Jordi Rovira<sup>2</sup>

<sup>1</sup>Department of Nephrology and Kidney Transplantation, Clínic Barcelona, Barcelona, Spain; <sup>2</sup>Laboratori Experimental de Nefrologia i Trasplantament (LENIT),(FRCB-IDIBAPS), Barcelona, Spain; <sup>3</sup>Department of Immunology, Clinic Barcelona, Barcelona, Spain





## P141 | Genetic engineering of limbs during *ex vivo* machine perfusion to overcome the unsolved hurdle of rejection Suganya Annadurai<sup>1</sup>, Sevval Besli<sup>1</sup>, Tamina Rother<sup>1</sup>, Yuliia Yuzefovych<sup>1</sup>, Nicco Krezdorn<sup>1</sup>, Rainer Blasczyk<sup>1</sup> and Constanca Figueiredo<sup>1</sup>

<sup>1</sup>Hannover Medical School, Germany;

#### P142 | Elucidating the sequence features driving KIR diversification

Jesse Bruijnesteijn<sup>1</sup>, Marit van der Wiel<sup>1</sup>, Nanine de Groot<sup>1</sup>, Ngoc Giang Le<sup>1</sup>, Natasja de Groot<sup>1</sup> and Ronald E. Bontrop<sup>1</sup>

<sup>1</sup>Biomedical Primate Research Centre, Netherlands

P143 | Cytomegalovirus (CMV) Intra-uterine transmission: involvement of KIR receptors-HLA ligand interactions Rosalia Cacciatore<sup>1</sup>, Annamaria Pasi<sup>1</sup>, Chiara Fornara<sup>2</sup>, Ilaria Sbarsi<sup>1</sup>, Paola Bergamaschi<sup>1</sup>, Carmen Tania Prezioso<sup>1</sup>, Carolina Radaelli<sup>1</sup>, Chiara Bottazzi<sup>1</sup>, Enrica Paudice<sup>1</sup>, Milena Furione<sup>1</sup>, Alessia Arossa<sup>1</sup>, Piera D'Angelo<sup>1</sup>, Fausto Baldanti<sup>1</sup>, Arsenio Spinillo<sup>3</sup>, Cesare Perotti<sup>1</sup> and Daniele Liller<sup>1</sup>

<sup>1</sup>Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; <sup>2</sup>Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy;

P144 | Post-injection monitoring of CAR-T cells targeting CD19 in the treatment of hematologic malignancies: quantitative PCR versus flow cytometry

Judith Desoutter<sup>1</sup>, Lucie Thirache<sup>1</sup>, Cécilia Da Costa<sup>1</sup>, Magalie Joris<sup>2</sup>, Lavinia Merlusca<sup>2</sup>, Lina Mustapha<sup>3</sup>, Christele Ossart<sup>4</sup>, Julien Lion<sup>1</sup> and Nicolas Guillaume<sup>1</sup>

<sup>1</sup>HLA Department, CHU Amiens Picardie, France; <sup>2</sup>Clinical Hematology, CHU Amiens Picardie, France; <sup>3</sup>Pharmacy, CHU Amiens Picardie, France; <sup>4</sup>Cellular Therapy, CHU Amiens Picardie, France

P145 Short Term Follow up of Soluble Immune Checkpoints in Renal Transplantation Cemil Pehlivanoğlu<sup>1</sup>, Başak Aru<sup>1</sup>, Ali Osman Gürol<sup>2</sup> and Gülderen Yanıkkaya Demirel<sup>1</sup> <sup>1</sup>Faculty of Medicine, Immunology Department, Yeditepe University, Istanbul, Turkey; <sup>2</sup>Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey

P146 | Analysis of HLA matching between deceased donors and cord blood units from a national bank network as a basis for potential platforms for chimerism-based immune tolerance after solid organ transplantation Roberto Crocchiolo<sup>1</sup>, Letizia Lombardini<sup>2</sup>, Nicoletta Sacchi<sup>3</sup>, Ilaria Lombardi<sup>2</sup>, John Blake<sup>4</sup>, David Allan<sup>4</sup>, Mohamad Sobh<sup>4</sup>, Francesca Puoti<sup>2</sup>, Silvia Trapani<sup>2</sup>, Anna Maria Gallina<sup>3</sup>, Marco Sacchi<sup>5</sup>, Simonetta Pupella<sup>6</sup>, Paola Bergamaschi<sup>7</sup>, Silvano Rossini<sup>1</sup> and Massimo Cardillo<sup>2</sup>

<sup>1</sup>ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; <sup>2</sup>Centro Nazionale Trapianti, Istituto Superiore di Sanità, Roma, Italy; <sup>3</sup>Italian Bone Marrow Donor Registry, E. O Ospedali Galliera, Genova, Italy; <sup>4</sup>Canadian Blood Service, Ottawa, Canada; <sup>5</sup>Coordinamento Regionale Trapianti, DG Welfare Regione Lombardia, Italy; <sup>6</sup>Centro Nazionale Sangue, Istituto Superiore di Sanità, Roma, Italy; <sup>7</sup>IRRCS Policlinico S. Matteo, Pavia, Italy

#### P147 | Possible Role of KIR3DL2/HLA-A\*11:01 Interaction in SARS-CoV-2 Infection Severity

**Maria Grazia Tupone<sup>1</sup>, Vincenza Cofini<sup>2</sup>, Carla Cervelli<sup>1</sup>, Raffaella Azzarone<sup>1</sup>, Olaida Valdez<sup>1</sup>, Maria Scimitarra<sup>1</sup>, Barbara Spaziani<sup>1</sup>, Stefano Necozione<sup>1</sup>, Antonia Petrucci<sup>3</sup>, Stefania Melena<sup>4</sup>, Michela Falco<sup>5</sup> and Franco Papola<sup>1</sup> <sup>1</sup>Regional Center for Immunohematology and Tissue Typing – ASL1 Abruzzo, L'Aquila, Italy; <sup>2</sup>Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy; <sup>3</sup>ASL2 Data Processing Center Lanciano, Vasto, Chieti, Italy; <sup>4</sup>Health Department – Pharmaceutical Assistance Service. Abruzzo Region., Italy; <sup>5</sup>Laboratory of Clinical and Experimental Immunology – IRCCS G.Gaslini. Genoa., Italy** 

P148 | Potential co-partnership in predisposition to Covid-19: KIR-HLA class I pairs control NK cells activity and T cells discriminate between HLA-C C1 and C2 groups in Antiviral Immunity

Carmen Tania Prezioso<sup>1</sup>, Annamaria Pasi<sup>2</sup>, Rosalia Cacciatore<sup>2</sup>, Ilaria Sbarsi<sup>1</sup>, Carolina Radaelli<sup>1</sup>, Paola Bergamaschi<sup>1</sup>, Chiara Bottazzi<sup>1</sup>, Enrica Paudice<sup>1</sup>, Federica Zavaglio<sup>1</sup>, Sara Bozzini<sup>1</sup>, Federica Meloni<sup>1</sup>, Lorenzo Cavagna<sup>1</sup>, Fausto Baldanti<sup>3</sup>, Daniele Lilleri<sup>1</sup> and Cesare Perotti<sup>1</sup> <sup>1</sup>Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; <sup>2</sup>IRCCS Policlinico San Matteo Pavia, Italy;

P149 KIR haplotyping using allele-level KIR typing results from NGSengine Max Diekman<sup>1</sup>, Sam Stokman<sup>1</sup>, Freek Manders<sup>1</sup>, Sake van Wageningen<sup>1</sup>, Bram Luiken<sup>1</sup> and Loes van de Pasch<sup>1</sup> <sup>1</sup>GenDx, Netherlands

P150 | TLR1 gene polymorphism in SARS-CoV-2 bilateral pneumonia

Alexander Evdokimov<sup>1</sup>, Ekaterina Peredelskaya<sup>1</sup>, Daria Stashkevich<sup>1</sup>, Svetlana Belyaeva<sup>2</sup>, Mikhail N. Vavilov<sup>2</sup> and Tatiana Suslova<sup>2</sup>

<sup>1</sup>Chelyabinsk State University, Russia; <sup>2</sup>Chelyabinsk Regional Hemotransfusion Station, Russia





## P151 | Allele-level characterization of KIR gene polymorphism in healthy elderly populations from Bulgaria, Romania and Turkey

Bushra Al Hadra<sup>1</sup>, Tsvetelin Lukanov<sup>1</sup>, Ileana Constantinescu<sup>2</sup>, Fatma Oguz<sup>3</sup>, Dimitri Apostol<sup>2</sup>, Yeliz Ogret<sup>3</sup>, Anastasiya Mihaylova<sup>1</sup> and Elissaveta Naumova<sup>1</sup>

<sup>1</sup>Clinic of Clinical Immunology and Stem Cell Bank, University Hospital Alexandrovska, Sofia, Bulgaria; <sup>2</sup>Carol Davila University of Medicine and Pharmacy; Centre for Immunogenetics and Virology, Fundeni Clinical Institute, Romania; <sup>3</sup>Department of Medical Biology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

#### P152 | Distribution of KIR genes in a Romanian cohort

Andreea Mirela Caragea<sup>1</sup>, Radu Ioan Ursu<sup>1</sup>, Alexandra Elena Constantinescu<sup>1</sup>, Ion Maruntelu<sup>1</sup>, Adriana Talangescu<sup>1</sup>, Mirela Maria Iacob<sup>2</sup>, Maria Tizu<sup>1</sup>, Alexandra Cojocaru<sup>1</sup>, Radu Alexandru Truica<sup>1</sup>, Larisa Denisa Visan<sup>2</sup>, Mariana Steluta Surugiu<sup>2</sup>, Corina Rotarescu<sup>2</sup> and Constantinescu Ileana<sup>2</sup>

<sup>1</sup>Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; <sup>2</sup>Centre for Immunogenetics and Virology, Fundeni Clinical Institute, Bucharest, Romania

#### P153 | Killer cell immunoglobulin-like receptor genes and their HLA ligands in southern Tunisia Sirine Louati<sup>1</sup>, Aida Charfi<sup>1</sup>, Imen Daoud<sup>1</sup>, Lilia Gaddour<sup>1</sup>, Faiza Hakim<sup>1</sup>, Ines Kammoun<sup>1</sup>, Bakhta Mallek<sup>1</sup>, Fadia Oualha<sup>1</sup>, Arwa Kamoun<sup>2</sup> and Nadia Mahfoudh<sup>1</sup>

<sup>1</sup>Immunology and <sup>1</sup>Histocompatibility Department, University Hedi Chaker Hospital, Sfax, Tunisia; <sup>2</sup>Immunology Department, Renal pathology research laboratory LR19ES11, University Hedi Chaker Hospital, Sfax, Tunisia

#### P154 | KIR/HLA Pairs in Southern Tunisia

Sirine Louati<sup>1</sup>, Aida Charfi<sup>1</sup>, Imen Daoud<sup>1</sup>, Lilia Gaddour<sup>1</sup>, Faiza Hakim<sup>1</sup>, Ines Kammoun<sup>1</sup>, Bakhta Mallek<sup>1</sup>, Fadia Oualha<sup>1</sup>, Arwa Kamoun<sup>2</sup> and Nadia Mahfoudh<sup>1</sup>

<sup>1</sup>Histocompatibility and Immunology Laboratory, Hedi Chaker Hospital, Tunisia; <sup>2</sup>Immunology Department, Renal pathology research laboratory LR19ES11, University Hedi Chaker Hospital, Sfax, Tunisia

#### **MHC EVOLUTION, POPULATION GENETICS**

#### P155 | Conserved extended 8.1 ancestral haplotype – the polymorphism beyond it

Marija Maskalan<sup>1</sup>, Danijela Svilicic<sup>1</sup>, Katarina Stingl Jankovic<sup>1</sup>, Marija Burek Kamenaric<sup>1</sup>, Zorana Grubic<sup>1</sup> and Renata Zunec<sup>1</sup>

<sup>1</sup>University Hospital Centre Zagreb, Croatia

## P156 | The strength of the humoral immune response to mRNA SARS-CoV-2 vaccination is influenced by HLA type of the vaccinee

Sendi Montanic<sup>1</sup>, Sabina Kunilo Jamnik<sup>1</sup>, Sonja Vuletić<sup>1</sup>, Urška Rahne Potokar<sup>1</sup> and Blanka Vidan Jeras<sup>1</sup> <sup>1</sup>Blood Transfusion Center of Slovenia, Slovenia

#### P157 | Allelic HLA-DPA1 ~ DPB1 haplotype analysis in a large Chinese population of 584 families Xiangjun Liu<sup>1</sup>, Yanling Zhang<sup>2</sup> and Junbo He<sup>3</sup>

<sup>1</sup>BFR Diagnostics, China; <sup>2</sup>Department of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China; <sup>3</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

P158 | Complement MHC Bf alleles show trans species evolution between man and chimpanzee Antonio Arnaiz-Villena<sup>1</sup>, Ignacio Juarez<sup>1</sup>, Christian Vaquero-Yuste<sup>1</sup>, Tomas Lledo<sup>1</sup>, Jose Manuel Martin-Villa<sup>1</sup> and Fabio Suarez-Trujillo<sup>1</sup>

<sup>1</sup>Dept Immunology, University Complutense, Medical School, Madrid, Spain

#### P159 | Genotypic Frequencies of Mutations Associated with Alpha-1 Anti-trypsin Deficiency in Unrelated Bone Marrow Donors from the Murcia Region Donor Registry in the Southeast of Spain

Irene Cuenca<sup>1</sup>, Carmen Botella<sup>1</sup>, Maria Rosa Moya-Quiles<sup>1</sup>, Jose Antonio Galian<sup>1</sup>, Helios Martinez-Banaclocha<sup>1</sup>, Marina Fernandez<sup>1</sup>, Alfredo Minguela<sup>1</sup>, Isabel Legaz<sup>2</sup> and Manuel Muro<sup>1</sup>

<sup>1</sup>Immunology Service. University Clinical Hospital "Virgen de la Arrixaca". Murcia. Spain, Spain; <sup>2</sup>Department of Legal and Forensic Medicine, University of Murcia (UMU), Murcia, Spain

## P160 | High-throughput genotyping of HLA-E, HLA-F and HLA-G and analysis of allele frequency distributions in Croatia

Lucija Jukic<sup>1</sup>, Marija Maskalan<sup>1</sup>, Marija Burek Kamenaric<sup>1</sup>, Katarina Stingl Jankovic<sup>1</sup>, Zorana Grubic<sup>1</sup>, Sanja Salamunovic<sup>1</sup> and Renata Zunec<sup>1</sup>

<sup>1</sup>University Hospital Centre Zagreb, Tissue Typing Centre Zagreb, Croatia





#### P161 | HLA association study with bipolar disorder in South Tunisian population Nadia Khlif<sup>1</sup>, Fatma Guermazi<sup>2</sup>, Aida Charfi<sup>1</sup>, Rihab Ouali<sup>2</sup>, Arwa Kamoun<sup>1</sup>, Ines Feki<sup>2</sup>, Faiza Hakim<sup>1</sup>, Lilia Gaddour<sup>1</sup>, Ines Kammoun<sup>1</sup>, Fedya Walha<sup>1</sup>, Jawaher Masmoudi<sup>2</sup> and Nadia Mahfoudh<sup>1</sup> <sup>1</sup>Histocompatibility Laboratory, Hedi Chaker Hospital, Sfax, Tunisia; <sup>2</sup>Psychiatry A Department, Hedi Chaker University Hospital, Sfax, Tunisia

## P162 | HLA-B, -C, -DRB1, -DQA1, and -DQB1 alleles involved in genetic predisposition to psoriasis, and psoriasis associated with psoriatic arthritis in East Croatian patients

Saška Marczi<sup>1</sup>, Mirjana Suver Stević<sup>1</sup>, Anđelka Bugarin<sup>1</sup>, Elizabeta Knezović<sup>1</sup> and Marina Samardžija<sup>1</sup> <sup>1</sup>University Hospital Osijek, Croatia

#### P163 | Genetic and Anthropological Relationships between Canary Islands and Azores Islands: The Saharo-Canarian Circle

Antonio Arnaiz-Villena<sup>1</sup>, Ignacio Juarez<sup>1</sup>, Christian Vaquero-Yuste<sup>1</sup>, Tomas Lledo<sup>1</sup> and Fabio Suarez-Trujillo<sup>1</sup> <sup>1</sup>Department of Immunology, Medicine School, University Complutense of Madrid, Spain

## P164 | The influence of HLA-DRB1 and HLA-DQB1 on post-transfusion alloimmunization with red blood cell antigens in Polish population

## Agnieszka Rzeszotarska<sup>1</sup>, Anna Piotrowska<sup>1</sup> and Jolanta Korsak<sup>1</sup>

<sup>1</sup>Military Institute of Medicine, Poland

blood cells (multi-responders). Additionally, a more frequent combined occurrence of HLA-DRB1\*07:01 and DRB1\*15:01 alleles was found in the group of people producing multi-specific antibodies to red blood cells (multi-responders).

#### P165 | HLA-G 3´UTR 14bp indel polymorphism in Southern Tunisian Bipolar Disorder patients

Aida Charfi<sup>1</sup>, Nadia Khlif<sup>1</sup>, Fatma Guermazi<sup>2</sup>, Imen Daoud<sup>1</sup>, Rihab Ouali<sup>2</sup>, Ines Feki<sup>2</sup>, Lilia Gaddour<sup>1</sup>, Faiza Hakim<sup>1</sup>, Fedya Walha<sup>1</sup>, Ines Kammoun<sup>1</sup>, Jawaher Masmoudi<sup>2</sup>, Arwa Kamoun<sup>1</sup> and Nadia Mahfoudh<sup>1</sup>

<sup>1</sup>Histocompatibility and immunology laboratory, Hedi Chaker Hospital, Tunisia; <sup>2</sup>Psychiatry A Department, Hedi Chaker University Hospital, Sfax, Tunisia

## P166 | Managing Possible New Alleles in Immunogenetics Laboratory of the Portuguese Institute of Blood and Transplantation, Porto

Maria Peixoto<sup>1</sup>, Susana Oliveira<sup>1</sup>, Filomena Mendes<sup>1</sup>, Vasco Guerra<sup>1</sup>, Rita Ferreira<sup>1</sup>, Manuel Dias<sup>1</sup> and Fátima Freitas<sup>1</sup>

<sup>1</sup>Portuguese Institute of Blood and Transplantation of Porto, Portugal

P167 | Linkage disequilibrium between MICA-129Met/Val and HLA-C1/C2 in the Russian population of the Chelyabinsk region of the Russian South Urals Mikhail N. Vavilov<sup>1</sup>, Tatiana Suslova<sup>1</sup> and Alexandra L. Burmistrova<sup>1</sup>

<sup>1</sup>Chelyabinsk State University, Russia

## P168 | HLA alleles and haplotypes in a Sudanese population and their relationship with Mediterraneans and East to West demic diffusion

Fabio Suarez-Trujillo<sup>1</sup>, Sayda El-Safi<sup>2</sup>, Christian Vaquero-Yuste<sup>1</sup>, Tomas Lledo<sup>1</sup>, Ignacio Juarez<sup>1</sup>, Jose Manuel Martin-Villa<sup>1</sup> and Antonio Arnaiz-Villena<sup>1</sup>

<sup>1</sup>Dept Immunology, University Complutense, Medical School, Madrid, Spain; <sup>2</sup>Ibn Sina Specialized Hospital, Khartoum, Sudan

#### P169 | Autonomic Study and Influence of UV Radiation on Evolution

Carlos Parga-Lozano<sup>1</sup>

<sup>1</sup>Research and Innovation Center CIIS and Fundacion Universitaria del Area Andina, Colombia

## P170 | Identification of HLA alleles involved in immune thrombotic thrombocytopenic purpura patients from Turkey

## Cevat Ilteris Kikili<sup>1</sup>, Demet Kivanc Izgi<sup>2</sup>, Damla Ortaboz<sup>3</sup>, Hayriye Senturk Ciftci<sup>2</sup>, Mustafa Nuri Yenerel<sup>4</sup>, Meliha Nalcaci<sup>4</sup>, Muhlis Cem Ar<sup>3</sup>, Fatma Savran Oguz<sup>2</sup> and Sevgi Kalayoglu Besisik<sup>4</sup>

<sup>1</sup>Istanbul University, İstanbul Faculty of Medicine, Department of Internal Medicine, Turkey; <sup>2</sup>Istanbul University Medicine of Faculty Department of Medical Biology, Turkey; <sup>3</sup>Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Hematology, Turkey; <sup>4</sup>Istanbul University, Istanbul Faculty of Medicine, Department of Adult Hematology, Turkey

## P171 | The frequency of HLA-B\*78:01 allele in the southern Tunisian population

Aida Charfi<sup>1</sup>, Arwa Kamoun<sup>1</sup>, Imen Daoud<sup>1</sup>, Faiza Hakim<sup>1</sup>, Ines Kammoun<sup>1</sup>, Bakhta Mallek<sup>1</sup>, Lilia Gaddour<sup>1</sup> and Nadia Mahfoudh<sup>1</sup>

<sup>1</sup>Immunology and histocompatibility Department, University Hospital Hedi Chaker, Sfax, Tunisia





#### P172 | Distribution of HLA antigens among patients with acute myeloid leukemia in the Republic of Kazakhstan Aida Turganbekova<sup>1</sup>, Zhulduz Zhanzakova<sup>1</sup>, Dana Baimukasheva<sup>1</sup>, Zhazira Saduakas<sup>1</sup>, Didara Khamitova<sup>1</sup> and Sanva Abdrakhmanova<sup>1</sup>

<sup>1</sup>Republican Scientific and Production Center for Transfusiology, Astana, Kazakhstan

## P173 | HLA-A, -B, -C, -DRB1, and -DQB1 allele and haplotype frequencies: An analysis of umbilical cord blood units at the Sichuan Cord Blood Bank

#### Qiang Chen<sup>1</sup>, Xingjie Li<sup>2</sup> and Jue Wang<sup>3</sup>

<sup>1</sup>Institute of Blood Transfusion, CAMS & PUMC and Sichuan Cord Blood Bank, China; <sup>2</sup>Sichuan Cord Blood Bank, China; <sup>3</sup>Institute of Blood Transfusion, CAMS & PUMC, China

## P174 | Identification of three novel HLA class I alleles, A\*24:556N, B\*55:129, and C\*01:02:87, found in Chinese cord blood units

#### Qiang Chen<sup>1</sup>, Xingjie Li<sup>2</sup> and Jue Wang<sup>3</sup>

<sup>1</sup>Institute of Blood Transfusion, CAMS & PUMC and Sichuan Cord Blood Bank, China; <sup>2</sup>Sichuan Cord Blood Bank, China; <sup>3</sup>Institute of Blood Transfusion, CAMS & PUMC, China

#### P175 | Detection of the HLA A\*02:275 allele, which was included in the HLA nomenclature in September 2022, in only one patient scheduled for hematopoietic stem cell transplantation: a single center experience. Sevim Gönen<sup>1</sup>, Cemre Demir<sup>2</sup>, Zühre Kaya<sup>3</sup> and Oğuz Söylemezoğlu<sup>3</sup>

<sup>1</sup>Gazi University Faculty of Medicine Tissue Typing (HLA) Laboratory, Turkey; <sup>2</sup>Diagnoseq Tissue Typing (HLA) Laboratory, Turkey; <sup>3</sup>Gazi Universit Faculty of Medicine Department of Pediatric Hematology, Turkey

#### **NEW TECHNOLOGIES IN IMMUNOGENETICS**

P176 | Revolutionizing high resolution HLA genotyping for transplantation assessment: validation, implementation and challenges of Oxford Nanopore Technologies' Q20+ sequencing Dianne De Santis<sup>1</sup>, Naser El-Lagta<sup>1</sup>, Linh Truong<sup>1</sup>, Fredrick Mobegi<sup>1</sup>, Laila Gizzarelli<sup>1</sup>, Irena Vukovic<sup>1</sup>, Scott Bazley<sup>1</sup>,

Wong Zo Ee<sup>1</sup>, Jess Rao<sup>1</sup>, Nichola Hugo<sup>1</sup>, Jacqueline Dey<sup>1</sup>, Doddi Venkat<sup>1</sup> and Lloyd D'Orsogna<sup>1</sup> <sup>1</sup>Department of Clinical Immunology, PathWest, Fiona Stanley Hospital, Australia

## P177 | The development of full gene multiplex PCR based assay for the non-classical HLA-E, HLA-F, HLA-G, HLA-H, MICA, and MICB genes.

#### Dianne De Santis<sup>1</sup>, Naser El-Lagta<sup>1</sup> and Lloyd D'Orsogna<sup>1</sup>

<sup>1</sup>Department of Clinical Immunology, PathWest, Fiona Stanley Hospital. University of Western Australia., Australia

#### P178 | Exploring ABO-histocompatibility: Luminex assay allows detection and characterization of endothelialtargeted ABO antibodies

#### Anne Halpin<sup>1</sup>, Francis Leier<sup>1</sup>, Bruce Motyka<sup>1</sup>, Caishun Li<sup>1</sup>, Simon Urschel<sup>1</sup>, Jean Pearcey<sup>1</sup>, Esme Dijke<sup>1</sup> and Lori West<sup>1</sup>

<sup>1</sup>University of Alberta, Alberta Precision Laboratories, Alberta Transplant Institute, Canada;

## P179 | Comparative assessment of cytometry by time-of-flight and full spectral flow cytometry based on a 33-color antibody panel

Antonia Schäfer<sup>1</sup>, Senan D'Almeida<sup>2</sup>, Julien Dorier<sup>3</sup>, Nicolas Guex<sup>3</sup>, Jean Villard<sup>1</sup> and Miguel Garcia<sup>3</sup> <sup>1</sup>Geneva University Hospital, Switzerland; <sup>2</sup>Viollier AG, Switzerland; <sup>3</sup>EPFL, Switzerland

## P180 | Rapid HLA High-Resolution Genotyping Utilizing Nanopore DNA Sequencing Technology for Allocation of Organs from Deceased Donors

## Diamanto Kouniaki<sup>1</sup>, Katerina Tarassi<sup>1</sup>, Vasiliki Kitsiou<sup>1</sup>, Theofilos Athanassiades<sup>1</sup>, Aikaterini Gkizori<sup>1</sup>, Georgia Galaziou<sup>1</sup> and Alexandra Tsirogianni<sup>1</sup>

<sup>1</sup>Immunology and Histocompatibility Department, Evangelismos General Hospital, Greece

#### P181 | NGS-Pronto: High throughput, high resolution HLA typing using nanopore sequencing Eline der Steege<sup>1</sup>, Sjoerd Creutzburg<sup>1</sup>, Bart Valkenburg<sup>1</sup>, Anna Hill<sup>1</sup>, Sake van Wageningen<sup>1</sup>, Marcel van de Streek<sup>1</sup>, Joris Albers<sup>1</sup>, Loes van de Pasch<sup>1</sup> and Pascal van der Weele<sup>1</sup>

<sup>1</sup>GenDx, Netherlands





## P182 | Validation of NGSTurbo typing with Nanopore sequencing for rapid and accurate HLA typing in deceased donor organ transplantation

Timo Olieslagers<sup>1</sup>, Carmen de Voijs<sup>1</sup>, Simone van der Linden<sup>1</sup>, Mathijs Groeneweg<sup>1</sup>, Christina Voorter<sup>1</sup> and Lotte Wieten<sup>1</sup>

<sup>1</sup>Maastricht University Medical Center, Netherlands

#### P183 | High-resolution HLA genotyping using nanopores – a multicenter study Stéphane Buhler<sup>1</sup>, Maja Nørgaard<sup>2</sup>, Rudi Steffensen<sup>3</sup>, Kirstine Kløve-Mogensen<sup>4</sup>, Bjarne Kuno Møller<sup>2</sup>, Rebecca Grossmann<sup>5</sup>, Sylvie Ferrari-Lacraz<sup>1</sup> and Claudia Lehmann<sup>5</sup>

<sup>1</sup>Transplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Dep. of Diagnostic, Geneva, Switzerland; <sup>2</sup>Department of Clinical Immunology, Aarhus University Hospital, Denmark; <sup>3</sup>Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark; <sup>4</sup>Dep. of Clinical Immunology, Aalborg University Hospital, Dep. of Clinical Medicine, Aalborg University, Denmark; <sup>5</sup>Laboratory for Transplantation Immunology, University Hospital Leipzig, Leipzig, Germany;

## P184 | Contribution of circulating donor-derived DNA in the prediction of kidney transplant rejection Thibault Pajot<sup>1</sup>, Isabelle Top<sup>1</sup> and Vincent Elsermans<sup>1</sup>

<sup>1</sup>CHU de Lille, France

#### P185 | Overcoming Challenges in KIR Gene Typing: A Third Generation Nanopore Sequencing Approach Laia Closa<sup>1</sup>, Cristina Ambrós<sup>1</sup>, Claudia Ulldemolins<sup>2</sup>, Francisco Vidal<sup>3</sup> and María José Herrero<sup>1</sup>

<sup>1</sup>Histocompatibility and Immunogenetics Laboratory, Blood and Tissue Bank, Barcelona, Spain; <sup>2</sup>Department of Immunology, Hospital Clínic, Barcelona, Spain; <sup>3</sup>Congenital Coagulopathy Laboratory, Blood and Tissue Bank, Barcelona, Spain

## P186 | HLA class I (HLA-A, -B, -C) Single Reaction, Full Gene, Unambiguous Genotyping by Technology Oxford Nanopore Sequencing

Vrushank Makwana<sup>1</sup>, Clare Nevin<sup>1</sup>, Ruifeng Zhang<sup>1</sup>, Rohan Raval<sup>1</sup>, Tom Browne<sup>1</sup> and Martin Howell<sup>1</sup> <sup>1</sup>Service Development Laboratory, NHS Blood and Transplant, Colindale, United Kingdom

#### P187 | Assessing the Performance of NG-Mix, a Novel Next Generation Sequencing Option developed by the Reagent Production Unit of the French Blood Center

Fabien Francois<sup>1</sup>, Béatrice Bardy<sup>1</sup>, Philippe Moskovtchenko<sup>1</sup>, Margot Lepage<sup>1</sup>, Dan-Adrian Luscalov<sup>1</sup>, Catherine Giannoli<sup>1</sup>, Xavier Fournel<sup>1</sup>, Celine Dard<sup>1</sup>, Pierre Fournier<sup>1</sup> and Valérie Dubois<sup>1</sup> <sup>1</sup>French Blood Center (Etablissement Français du Sang, EFS), France

P188 Assessment of HLA Typing and Post-Transplant Monitoring Combined on a Single NGS Run Amanda Willis<sup>1</sup>, Curt Lind<sup>1</sup>, Thomas Morris<sup>1</sup>, Andrea Zimmerman<sup>1</sup>, Thomas Hsiao<sup>1</sup> and Beata Kmiec<sup>2</sup> <sup>1</sup>CareDx, United States; <sup>2</sup>CareDx, Sweden

P189 | Validation of AlloSeq cfDNA to detect Donor Derived Cell-Free DNA (dd-cfDNA) from renal transplant recipient (RTR) blood samples extracted using the Promega-Maxwell® RSC ccfDNA LV Plasma Kit Selda Duman<sup>1</sup>, Nicola Thal<sup>2</sup>, Madalina Pinzaru<sup>1</sup>, Sharon Vivers<sup>3</sup>, Sandra Frater<sup>1</sup>, Lisa Walsh<sup>1</sup>, Franco Tavarozzi<sup>1</sup> and Raymond Fernando<sup>2</sup>

<sup>1</sup>Anthony Nolan Laboratories, London, United Kingdom; <sup>2</sup>Anthony Nolan Laboratories, London, UK and Solid Organ Group, Royal Free Hospital, London, United Kingdom; <sup>3</sup>Anthony Nolan Laboratories, London, UK and UCL Cancer Institute, UCL Campus, London UK, United Kingdom;

P190 | High-Resolution full gene HLA-DRB1 genotyping using Oxford Nanopore long read sequencing technology Ruifeng Zhang<sup>1</sup>, Rohan Raval<sup>1</sup>, Clare Nevin<sup>1</sup>, Vrushank Makawana<sup>1</sup>, Tom Browne<sup>1</sup> and Martin Howell<sup>1</sup> <sup>1</sup>NHS Blood and Transplant, United Kingdom

#### P191 | MICA & MICB – Are your samples up to the challenge?

Nicola Brosnan<sup>1</sup>, Evelien Little<sup>1</sup>, Selda Duman<sup>1</sup>, Jade Kally<sup>1</sup>, Sharon Vivers<sup>2</sup>, Reetinder Grewal<sup>1</sup>, Raymond Fernando<sup>3</sup>, Lisa Walsh<sup>1</sup> and Franco Tavarozzi<sup>1</sup>

<sup>1</sup>Anthony Nolan Histocompatibility Laboratories, London, United Kingdom; <sup>2</sup>Anthony Nolan Histocompatibility Laboratories, London, UK; UCL Cancer Institute, UCL Campus, London UK, United Kingdom; <sup>3</sup>Anthony Nolan Histocompatibility Laboratories, London, UK; Solid Organ Group, Royal Free Hospital, London, United Kingdom

P192 | High Resolution HLA Typing Comparative Analysis of Blood Stem Cell and Solid Organ Donors and Recipients with Next Generation Sequencing and Real Time PCR Chryso Pierides<sup>1</sup>, Andri Papaloizou<sup>1</sup>, Georgios Kallis<sup>1</sup>, Maria Kyriakou<sup>1</sup>, Efi Streppa<sup>1</sup> and Paul Costeas<sup>1</sup> <sup>1</sup>The Karaiskakio Foundation, The Center for the Study of Haematological Malignancies, Cyprus;





## P193 | Nanopore kit for the detection of new alleles

Pascal Pedini<sup>1</sup>, Coralie Frassati<sup>1</sup>, Agnès Basire<sup>1</sup>, Maxime Raz<sup>2</sup>, Jacques Chiaroni<sup>1</sup> and Christophe Picard<sup>1</sup> <sup>1</sup>Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France; <sup>2</sup>Service de Transfusion Sanguine, Centre Hospitalier de Nouméa,

Annunogenetics Laboratory, Etablissement Français du Sang, Marseille, France; Aservice de Transfusion Sanguine, Centre Hospitalier de Nouméa, Noumea, New Caledonia

## P194 | Nanotype and nanopore sequencing – a rapid and reliable technology for routine HLA typing Ana Moise<sup>1</sup>, Ruxandra Caisan<sup>1</sup> and Irina Monica Dutescu<sup>1</sup>

<sup>1</sup>National HLA Laboratory, National Institute of Blood Transfusion Prof dr. C. T Nicolau, Bucharest, Romania

#### P195 | Deceased Donor HLA typing by Next Generation Sequencing – Ready for Prime time! Cathi Murphey<sup>1</sup>, Fernando Garcia<sup>1</sup>, Ellie Saunders<sup>1</sup>, Cody Murray<sup>1</sup> and Shannon Mesa<sup>1</sup>

<sup>1</sup>Southwest Immunodiagnostics, Inc., United States;

## P196 | Comparing MFI and MCI in single antigen HLA antibody detection on alternative platforms (Luminex vs HISTO SPOT microarrays)

## Murielle Verboom<sup>1</sup> and Kristin Launhardt<sup>2</sup>

<sup>1</sup>Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany; <sup>2</sup>BAG Diagnostics GmbH, Germany

## P197 | Utilization of PreSorb beads in removing nonspecific reactivities in HLA antibody test by Luminex solid phase single antigen beads assay: a single center experience

Zeying Du<sup>1</sup>, Charles Williams<sup>1</sup>, Rachel Bosai<sup>1</sup> and Mohamed Elrefaei<sup>1</sup>

<sup>1</sup>Mayo Clinic Florida, United States

## P198 | Rapid and accurate monolocus HLA typing using Oxford Nanopore Technology: new routine for the "HLA and disease" activity at Bordeaux University Hospital

## Mamy Ralazamahaleo<sup>1</sup>, Océane Tenchon<sup>2</sup>, Elodie Wojciechowski<sup>1</sup>, Marine Cargou<sup>1</sup>, Jonathan Visentin<sup>2</sup> and Gwendaline Guidicelli<sup>1</sup>

<sup>1</sup>Laboratoire d'Immunologie et Immunogénétique, Groupe Hospitalier Pellegrin, CHU de Bordeaux, France; <sup>2</sup>Laboratoire d'Immunologie et Immunogénétique, CHU de Bordeaux et CNRS, ImmunoConcEpT, Université de Bordeaux, France

#### P199 | Genotyping of six HLA-G SNPs by oligonucleotide ligation assay: optimization of the technique Imen Daoud<sup>1</sup>, Sirine Louati<sup>2</sup>, Aida Charfi<sup>2</sup>, Lilia Gaddour<sup>2</sup>, Faiza Hakim<sup>2</sup>, Ines Kammoun<sup>2</sup>, Fadia Oualha<sup>2</sup>, Bakhta Mallek<sup>2</sup>, Arwa Kamoun<sup>3</sup> and Nadia Mahfoudh<sup>2</sup>

<sup>1</sup>Hedi Chaker Hospital of Sfax, Tunisia; <sup>2</sup>Immunology and Histocompatibility Department, University Hedi Chaker Hospital, Sfax, Tunisia; <sup>3</sup>Histocompatibility Department, Renal Pathology Research Laboratory LR19ES11, Hedi Chaker Hospital, Sfax, Tunisia;

P200 Assessment of automated cell-free DNA extraction utilizing Promega Maxwell Amanda Willis<sup>1</sup>, Thomas Morris<sup>1</sup>, Curt Lind<sup>1</sup> and Thomas Hsiao<sup>1</sup> <sup>1</sup>CareDx, United States

P201 Analytical and clinical validation of the One Lambda™ Devyser Accept cfDNA kit Pascal Pedini<sup>1</sup>, Nisem Cherouat<sup>1</sup>, Alizée Sebastian<sup>1</sup>, Benjamin Coiffard<sup>2</sup>, Agnès Basire<sup>1</sup>, Jacques Chiaroni<sup>1</sup>, Martine Reynaud-Gaubert<sup>2</sup>, Coralie Frassati<sup>1</sup> and Christophe Picard<sup>1</sup>

<sup>1</sup>Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France; <sup>2</sup>Lung Transplant Department, APHM, Marseille, France

## P202 | Validation of NGS and intermediate resolution methods for HLA typing at the Laboratorio Nacional de Inmunogenética – INCUCAI of Argentina

Pablo Galarza<sup>1</sup>, Maria Fernanda Yaunguzian<sup>1</sup>, Lucas Monzon<sup>1</sup>, Maria Belén Balekjian<sup>1</sup>, Laura Aguerre<sup>1</sup>, Cecilia Delfino<sup>1</sup>, Richard Malan<sup>1</sup> and Carlos Soratti<sup>1</sup>

<sup>1</sup>INCUCAI, Argentina

**P203** | NanoTYPE – From single locus testing to High Throughput Multiplexing in 96 format Celine Dard<sup>1</sup>, Gregory Werner<sup>2</sup> and Mathieu Dewez<sup>3</sup> <sup>1</sup>EFS Auvergne Rhône Alpes, France; <sup>2</sup>Omixon Biocomputing Ltd, Switzerland; <sup>3</sup>Omixon Biocomputing Ltd, France

P204 | Evaluation of LabScreen PreSorb to proficiently remove pan-reactive DR antibody reactivity Aisling O'Brien<sup>1</sup>, Catherine Owens<sup>1</sup>, Patricia Mullany<sup>1</sup>, Joseph Kelly<sup>1</sup> and Mary Keogan<sup>1</sup> <sup>1</sup>National Histocompatibility & Immunogenetics Service for Solid Organ Transplant, Beaumont Hospital, Dublin, Ireland





P205 | Detection and characterization of six novel HLA alleles by next-generation sequencing in a Spanish population during the last year

Amalia Tejeda<sup>1</sup>, Jairo Eduardo Niño-Ramírez<sup>1</sup>, Daniel Arroyo-Sánchez<sup>1</sup>, Antonio Balas<sup>2</sup>, Isabel Jiménez Hernaz<sup>1</sup>, Pilar Terradillos-Sánchez<sup>1</sup>, Ariadna Vicente Parra<sup>1</sup>, Beatriz García Martín<sup>1</sup>, Yasmín Roldán<sup>1</sup>, Ana Balanzategui<sup>1</sup>, Miguel Alcoceba<sup>1</sup>, Ramón García Sanz<sup>1</sup> and Francisco Javier Gil-Etayo<sup>1</sup>

<sup>1</sup>Laboratorio de HLA-Biología Molecular, Servicio de Hematología, Hospital Universitario de Salamanca, Spain; <sup>2</sup>Histocompatibilidad, Centro de Transfusión de la Comunidad de Madrid, Spain;

#### P206 | Deciphering alloreactivity: an educational website tailored to teach and learn alloreactivity. Adèle Dhuyser<sup>1</sup>, Cassandra Michel<sup>2</sup> and Alice Aarnink<sup>1</sup>

<sup>1</sup>HLA and Histocompatibility Laboratory, CHRU de Nancy & IMoPA6, UMR7365 CNRS, Université de Lorraine, Nancy, France; <sup>2</sup>Université de Lorraine, Vandoeuvre-les-Nancy, France





## **SATELLITE SYMPOSIA**

WERFEN, MAY 21, 2024, 12:10–12:50, HALL A Title: Virtual crossmatch in Eurotransplant: A one-year experience



Cynthia Kramer, PhD Post-doc, Transplantation Immunology group, Eurotransplant Reference Laboratory, Dept. of Immunology, Leiden University Medical Center, The Netherlands

## CAREDX, MAY 21, 2024, 13:10–13:50, HALL B

Title: Transplantation Excellence: Innovative Solutions for Enhanced Patient Care



Implementation of NGS-Based HLA typing, AlloSeq Tx Assay, for Donor Registry in Saudi Arabia Abdullah N. Alsuwaidan, MD FCAP Dept. of Pathology & Laboratory Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

**Long-Term Integrity of Transplanted Stem Cells in Human Recipients** Mirjam Belderbos, MD, PhD *Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands* 

**Putting dd-cfDNA into Practise: Clinical Experience from the Hospital Clínic of Barcelona** David Cucchiari, MD, PhD *Renal Transplant Unit, Hospital Clínic, Barcelona, Spain* 

## OMIXON, MAY 21, 2024, 17:30-18:10, HALL A



**BIG STEP TOWARDS DIAGNOSTICS WITH NANOPORE SEQUENCING** Dr. Claudia Lehmann

University Hospital Leipzig, Germany, Laboratory for Transplantation

#### DONOR-DERIVED cfDNA AS DIAGNOSTIC TOOL IN KIDNEY TRANSPLANTATION

Karin Boer, PhD Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands

## INTRODUCTION OF NANOTYPE IN THE HLA TYPING ROUTINE ACTIVITY OF A FRENCH HISTOCOMPATIBILITY IMMUNOGENETICS LABORATORY

Romain FERRU-CLEMENT, PhD Immunogenetics Laboratory, French Blood Centre, Site of Poitiers, France





#### HANSA BIOPHARMA, MAY 21, 2024, 17:30-18:10, HALL C

Title: From delisting to organ acceptance for HLAi kidney transplantation – with or without desensitisation



**Chair:** Dr. Fadi Haidar *Hopitaux Universitaires Geneve, Geneva, Switzerland* 

**Speaker:** Dr. Dave Roelen Leiden University Medical Centre (LUMC), Leiden, The Netherlands

**Speaker:** Dr. Jean Mihes Hopital Purpan – CHU de Toulose, Toulose, France

THERMO FISHER SCIENTIFIC, MAY 22, 2024, 12:10–12:50, HALL A Title: Post-transplant monitoring in the era of dd-cfDNA and single antigen bead analysis

## **Thermo Fisher**

SCIENTIFIC

Jakob Nilsson M.D., Ph.D. Consultant Physician, Director Transplant Immunology, University Hospital Zurich, Switzerland

GENDX, MAY 22, 2024, 13:10–13:50, HALL A Title: Timeless Expertise: Innovations in HLA Typing



T. Olieslagers Biomedical Scientist at Maastricht University Medical Center

M. Rijkers, PhD Project Manager R & D GenDx





## PARTNERS

#### **PLATINUM PARTNERS**



#### CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre-and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. With over 20 years of leadership in 4 areas of transplant innovation, our understanding of transplant patients and care teams allows us to develop solutions to extend graft life. With two decades of commitment to transplant care, we have developed close partnerships across the transplant ecosystem that grow stronger every day. CareDx is a global, 100% transplant focused company, demonstrating leadership in serving laboratories, researchers, and clinicians with its state-of-the-art product portfolio of next-generation sequencing (NGS) based AlloSeq products, which serve as pre- and post-transplantation solutions. For pre-transplant application, CareDx offers HLA typing solutions QTYPE and AlloSeq Tx. For post-transplantation monitoring, CareDx offers AlloSeq HCT chimerism testing and AlloSeq cfDNA for labs to measure the relative amount of donor derived cfDNA (dd-cfDNA) in solid organ transplant recipients. All products are CE marked. For research purposes, CareDx also provides AlloSeq Tx and AlloSeq cfDNA testing as services for customers who prefer to use the CareDx service lab in Stockholm, Sweden. Learn more about CareDx transplant lab products: https://caredx.com/products-and-services/transplant-lab-products/



#### **GENDX**

3584 CM Utrecht | Utrecht Science Park The Netherlands | +31 (0)30 252 3799 | www.GenDx.com NGS-Pronto® High-Resolution Nanopore HLA typing NGS-Pronto offers amplification and library preparation reagents, complete with 96 barcodes, providing for an easy and efficient workflow. After nanopore sequencing the data can be directly analysed with GenDx software – NGSengine®-Turbo. Learn more at www.gendx.com/product\_line/ngs-pronto/ Our products GenDx develops and offers a comprehensive line of reagents and services, analysis software, and education. NGS Chimerism Monitoring experts in transplant diagnostics Education Alexander Numan Building Yalelaan 48 3584 CM Utrecht the Netherlands Phone: +31 30 2523799 Cumberland Metro Office Park 5521 N. Cumberland Avenue Suite 1116 Chicago, IL 60656 USA Phone: +1 312 815 5006 info@gendx.com www.GenDx.com COMING SOON A





## Thermo Fisher

### **Thermo Fisher Scientific**

We take pride in our Mission: We enable our customers to make the world healthier, cleaner and safer Customers worldwide trust Thermo Fisher Scientific products and services to help them accelerate innovation and enhance productivity. Together, we are advancing science to make a real dierence. We do that by providing an unmatched combination of innovative technologies, purchasing convenience and comprehensive support through these and other product and service brands: Discover more © 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Information accurate as of posting date, 07-February-2024. R&D investment is calculated based on 2023 figures. Fact sheet >1,000,000 products >120,000 colleagues \$1.3B/YR invested in R&D >\$40B in revenue The Transplant Diagnostics Division of Thermo Fisher Scientific As part of Thermo Fisher Scientific, we oer products and services to advance the science of transplant diagnostics. Our solutions help transplant labs and clinical teams provide personalizedcare across the patient experience. Dr. Paul Terasaki founded One Lambda™ in 1984 with the goal of developing tests to improve how laboratories match and monitor transplant recipients and donors. Since then, our HLA typing and antibody detection assays have been trusted by transplant laboratories worldwide. Clinicians also rely on data from our patient monitoring tests to make important decisions about post-transplant therapies. Transplantation is life-changing for recipients, and clinical diagnostics play a vital role in supporting all phases of treatment. Through our commitment to scientific innovation, product quality, patient advocacy, and excellent customer service, we are helping the transplant community raise the

## werfen

#### Werfen

#### **Powering Patient Care:**

Werfen is a growing, family-owned, innovative company founded in 1966 in Barcelona, Spain. We are a worldwide leader in specialized diagnostics in the areas of Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant. Through our Original Equipment Manufacturing (OEM) business line, we research, develop, and manufacture customized assays and biomaterials. We operate directly in 30 countries and in more than 100 territories through distributors. Our Headquarters and Technology Centers are located in the US and Europe, and our workforce is more than 7.000 strong.

#### **SILVER SPONSORS**



#### **OMIXON BIOCOMPUTING LTD.**

Omixon is a global transplantation diagnostic company with a mission to provide histocompatibility laboratories with innovative technologies to improve transplant outcomes. Omixon is headquartered in Budapest, Hungary, with operations in the United States, Brazil and the Netherlands serving more than 100 laboratories worldwide. Building on multidisciplinary competences in bioinformatics, software engineering, molecular biology and regulatory science, Omixon transforms molecular biology innovations into state-ofthe-art products in transplant diagnostics. Omixon was the first to successfully introduce a next generation sequencing (NGS) based HLA genotyping kit and software in 2014 by bringing Holotype HLA product and HLA Twin software to market. HLA Twin delivers a leading software in high-resolution HLA genotyping and is used in more than 100 laboratories worldwide. Omixon was the first to release a high resolution HLA with less than 5 hours turnaround time on the Oxford Nanopore sequencing platform complemented by NanoTYPER analysis software. In 2024 Omixon introduces HoloGRAFT ONE RUO with a promise of frequent and affordable testing of donor-derived cell-free DNA (dd-cfDNA) levels.







#### Hansa Biopharma

Hansa Company short description – Mar 2024 Hansa Biopharma is based in Lund, Sweden with operations in other European countries and the U.S. Hansa leverages its proprietary antibody-cleaving enzyme technology platform to target pathogenic and disease causing antibodies. Hansa's lead product, imlifidase, is an antibody-cleaving enzyme which enables kidney transplantation in highly sensitized patients. The European Commission conditionally approved Idefirix (imlifidase) for the desensitization of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor with use reserved for patients unlikely to be transplanted under available kidney allocation systems including prioritisation programmes for highly sensitised patients.



#### DiagnoSeq

Diagnoseq Genetic Diseases Evaluation Center (GDEC) as one of the largest "Genomic Service Provider" in Turkey and one of the largest "HLA Tissue Typing" laboratories in Europe offers extensive services either as raw data or as clinical report to its customers. Diagnoseq adopts medical ethics, good laboratory practices, information security and confidentiality as its basic principles. Diagnoseq Tissue Typing Laboratory received EFI (European Federation of Immunogenetics) accreditation in 2018, ISO 27001 certification in 2022 and has also successfully completed the CAP Accreditation (College of American Pathologists) in 2023. Diagnoseq with its advanced technology infrastructure provides short turnaround times to deliver the results in as short as 5 days for NGS based HLA Typing and 10 days for Whole Exome Sequencing (WES) and Clinical Exome Sequencing (CES).

#### **BRONZE SPONSORS**











## **SOCIAL NETWORKING EVENTS**

## WELCOME COCKTAIL

Monday, May 20, 2024, 19:30–21:30Place:Exhibition HallThe Welcome Cocktail is open to all conference participants.

## **NETWORKING EVENT**

Wednesday, May 22, 2024, 19:45–01:00		
Price:	105 € / per person	
Place:	Domain Du Grand Malagny, 48-50 Route de Malagny, 1294 Genthod	
Transportation:	Transportation from the venue and vice versa will be provided by shuttle buses	
Dress code:	Business casual/smart casual. Comfortable shoes are recommended	

## **GENDX TULIP RUN (5 KM)**

Wednesday, May 22, 2024, from 06:40		
Price:	25 € / per person	
Meeting point:	the main entrance of the Palexpo Geneva at 6:15	
<b>Detailed schedule:</b>	06:40 – Warm-up	
	07:00 – Start run	
	08:00 – Tulip run awards & heading back to the hotel	





## Join us at our EFI **2024 Symposium**

Margot D., Stem Cell Transplant Recipien

## **Transplantation Excellence: Innovative Solutions for Enhanced Patient Care**

**Tuesday 21 May, 2024** Time: 13.10 - 13.50



## Save the date to explore insights into the future of pre- and post-transplant excellence



## **Moderator**

Hall: B

Curtis Lind - VP, Head of R&D Products CareDx



## **Guest Speakers**

Implementation of NGS-Based HLA typing, AlloSeq Tx Assay, for Donor Registry in Saudi Arabia Abdullah N. Alsuwaidan, MD, FCAP Department of Pathology & Laboratory Medicine King Faisal Specialist Hospital & Research Center Riyadh, Saudi Arabia



Long-Term Integrity of Transplanted Stem Cells in Human Recipients Mirjam Belderbos, MD, PhD Princess Máxima Center for Pediatric Oncology Utrecht, the Netherlands



Putting dd-cfDNA into Practice: Clinical Experience from the Hospital Clínic of Barcelona David Cucchiari, MD, PhD Renal Transplant Unit, Hospital Clínic Barcelona, Spain







AlloSeq Tx, AlloSeq Assign, AlloSeq HCT, AlloSeq HCT Software, AlloSeq cfDNA and AlloSeq cfDNA Software are available as CE/IVD and Research Use only. For local regulatory status, please contact CareDx. AlloSeq cfDNA is only available outside of the United States. AlloSeq is a trademark or registered trademark of CareDx, Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. Research Use Only products are not to be used for diagnostic procedures. © 2024 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.



# AlloSeq Tx

## Better Matching. Better Method.

THE NEXT GENERATION IN GENETIC MATCHING WITH INNOVATIVE HYBRID-CAPTURE TECHNOLOGY

> Margot D., Stem cell transplant recipient

**Expandable Gene Content** without Affecting Lab Workflow

Easy Single Tube Workflow with Early Indexing Step

No Long-range PCR = No Amplification Inefficiencies


Fast Software Analysis with Data Upload at 1 min/sample\*

\*as per internal testing

#### Availability

AlloSeq Tx9 (HLA-A, -B, -C, -DRB1/3/4/5, DQB1, DPB1) covers classical HLA loci

AlloSeq Tx17 (HLA-A, -B, -C, -E, -F, -G, -H, DRB1/3/4/5, DQA1, DQB1, DPA1, DPB1) moves beyond the traditional transplant related loci to consider more transplant associated genes



## For more information visit https://CareDx.com/AlloSeqTx or reach out to your local CareDx representative.

AlloSeq Tx reaction kits are CE/IVD in the EU and UK and available as Research Use Only for the rest of the world (i.e., US). For local regulatory status of AlloSeq products, please contact CareDx. AlloSeq Tx kits are not used for the diagnosis of disease. AlloSeq is a trademark or registered trademark of CareDx Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. © 2023 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.

## AlloSeq cfDNA

## Risk Assessment of Allograft Rejection by Measuring dd-cfDNA

An innovative NGS-based solution that enables dd-cfDNA blood testing as a CE-IVD kit for laboratory implementation or send out service

Derrick C, kidney transplant recipient

## **NGS Based CE-IVD Kit**

- + Targets 202 bi-allelic SNPs across 22 autosomes
- + Escalate testing up to 24 samples/run
- + From cfDNA sample to sequencing < 1.5 hrs hand-on time
- + Validated on Illumina MiniSeq and MiSeq

- + No prior genotyping required
- + Multiplexed amplification of targets & sample indexing/barcoding into one single reaction
- + Low cfDNA input of 10ng
- + Ability to monitor more than one donor cfDNA contributor\*

#### Send Out Service

## + Get your results through our high-quality send out service with short turn around time



Easy sample collection process | Technical expertise | Full logistics support No lab setup or NGS equipment required | Cost and resource effective

AlloSeq cfDNA is CE/IVD in the EU and in the UK and Research Use Only for the rest of the world. For local regulatory status, please contact CareDx. AlloSeq Service is Research Use Only. Research Use Only products are not to be used for diagnostic procedures. AlloSeq is a trademark or registered trademark of CareDx Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. © 2023 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights researved.



\* Would require recipient genotyping

MAR121 Revision 1 Effective 2023-06



# COMING SOON DISCOVER NGS-Pronto®

HIGH GENE COVERAGE

## ⊘ High-Resolution HLA Typing

## Multiplex amplification 11 loci

## Oxford Nanopore Sequencing



Only 15 min. sequencing/sample



Run up to 96 samples at a time



Full phasing No fragmentation



Dedicated software NGSengine®-Turbo



## Interested?

Contact us for more information at support@gendx.com GenDx | +1 (312) 815 5006 | www.GenDx.com



# ORDER NOW NGS-Turbo<sup>®</sup> HIGH-RESOLUTION HLA TYPING WITHIN 3 HOURS


OUR SOLUTION FOR NANOPORE HLA SEQUENCING

## Fast and easy

With a turnaround time of less than three hours and an easy and robust workflow, NGS-Turbo® is designed for HLA typing in situations where time is a critical factor. In combination with Oxford Nanopore Technology sequencing devices, accurate sequencing-based HLA typing results are generated at incredible speed.

## Workflow simplicity

The NGS-TurboAmp kit offers 11 HLA loci using a whole-gene approach. The extremely quick 1-tube library preparation with NGS-TurboPrep requires no fragmentation and can be safely paused at any time. After nanopore sequencing the data can be directly analyzed with NGSengine®-Turbo.





Yalelaan 48 | 3584 CM Utrecht | Utrecht Science Park The Netherlands | +31 (0)30 252 3799 | www.GenDx.com





# Chimerism monitoring by NGS NGStrack<sup>®</sup> & TRKengine<sup>®</sup>



13;

# Quick & easy data analysis with TRKengine

- 🖉 Reliable at all chimerism %
- 🚺 Up to 0.1% sensitivity
- Only 60 ng DNA needed per sample



131

## Interested?

Contact us for more information at support@gendx.com GenDx | +1 (312) 815 5006 | www.GenDx.com

## Thermo Fisher SCIENTIFIC

# Join us at booth #3

We'll be showcasing our assays, protocols and software as our advancements continue to reshape the landscape of HLA genotyping and antibody detection technologies.



Join the Community

()





# Join us at our industry symposia

## Wednesday, 22<sup>nd</sup> May 12.10 – 12.50 | Hall A

# Post-transplant monitoring in the era of dd-cfDNA and single antigen bead analysis

Jakob Nilsson M.D., Ph.D. Consultant Physician, Director Transplant Immunology University Hospital Zurich



## Redefining HLA antibody isolation, bead by bead

This innovative assay isolates individual HLA antibodies from human serum in a targeted manner using adsorption and elution via antigen-coated magnetic beads.

One Lambda<sup>™</sup> MagSort<sup>™</sup> utilizes a comprehensive panel of 59 HLA antigens across 6 loci, individually coupled to magnetic beads. The ability to elute specific antigens of interest provides a more focused dataset and provides users with a robust and standardized approach.

## Capabilities

## Targeted technology

- Individual antigen-coated magnetic beads
- Elute antibodies that bind to a specific antigen
- Results in a more focused HLA antibody assessment

### Customizable panels

- 59 antigens across 6 locus specific kits
- · Flexibility to focus only on antigens of interest
- Coverage across well-documented antigens

#### Efficient workflow

- Up to 45 minutes of hands-on time and as little as 4 hours to workflow completion
- Uses equipment already found in most laboratories
- Immediate antigen availability.

For more information on this new product, visit the Thermo Fisher Scientific booth



Change can be intimidating, but without change there is limited growth. Differences in MFI values between vendors can be challenging to explain, but they should not be seen as a determent. There are many ways to help overcome MFI differences between vendors and with the right partner and tools you can overcome this barrier. As Darwin said, "It is not the strongest that survive, nor the most intelligent, but the ones that are most adaptable to change."

**<u>CLICK HERE</u>** to find out what your peers experienced by adapting to change.

werfen.com

Transplant

werfen

Rev1-MAR2024

werfen

# GROWTH.

# Looking for ways to advance your HLA antibody analysis knowledge?

Antibody analysis can be complex and overwhelming. With staff turnover it can be difficult to train new employees on analysis creating a greater burden on existing staff. Immucor's MATCH IT!<sup>®</sup> Antibody software is specifically designed for simplifying the complexities of HLA analysis. Adaptive, effective and powerful, MATCH IT!<sup>®</sup> Antibody software will turn any tech into an antibody analysis expert.

**CLICK HERE** to see how you can become an expert.

#### werfen.com

Rev1-MAR2024

# EVOLVE.



werfen

## Looking for more solutions to help aid in your decision making process?

How could more tools in your toolbox better aid you in your decision making process for critical transplant patients? When you have more information at your disposal, you can optimize your decision making process for better efficiency and delivery of results. Make the best use of your valuable time by adding LIFECODES Single Antigen Class I and Class II to your workflow.

**<u>CLICK HERE</u>** to see how a fellow member of the HLA community has accomplished this.

#### werfen.com

Rev1-MAR2024



## ABOUT US

Diagnoseq Genetic Diseases Evaluation Center (GDEC), one of the largest "Genomic Service Provider" in Turkey and one of the largest "HLA Tissue Typing" laboratories in Europe offers extensive services, as raw data or as clinical report to its customers.

## SERVICES

We provide the highest quality HLA Typing and Genomic services. Our mission, as a high throughput NGS laboratory is to provide the most efficient solutions to our customers for Tissue Typing and other genomics services (WES, WGS, Molecular Karyotyping, Oncology)

We welcome opportunities to cooperate in the areas where you can benefit from our services.





## **EFI ACCREDITATION**

The European Federation for Immunogenetics (EFI) awards the EFI certificate to laborories that the quality requirements set by EFI (Standards). EFI is a European organisation that focuses on immunogenetics, tissue typing and transplantation. The EFI certificate is required by a number of organisations operating in the field of stem cell and solid organ transplantation including JACIE, NMDP and the Eurotransplant foundation.



## **CAP ACCREDITATION**

The CAP accredits laboratories performing testing on specimens from human beings or animals, using methodologies and clinical application within the expertise of the program. CAP Laboratory Accreditation helps laboratories: Maintain accuracy of test results and ensure accurate patient diagnosis. Meet required standards from CLIA, FDA and OSHA. CAP requirements commonly exceed the standards, bolstering patient care and safety.



#### **ISO 15189**

ISO 15189 standard; Based on ISO/IEC 17025 and ISO 9001, it aims to ensure safety in medical laboratories, the accuracy and required by patients and clinical staff directly responsible for treatment.



## ISO 27001

Internationally recognized ISO/IEC 27001 is an excellent framework for managing and protecting our information assets to keep them safe and secure. In order to protect personal data and sensitive information, ISO/IEC 27001 standard enables implementation of a robust approach to manage information security in our organization.

## REFERENCES 🏐



We are proud to provide services to the Donor Registry of Turkiye (TURKOK) and performed more than 1 million HLA Typing.

CONTACT US
DiagnoSeq Genetic Diseases Assessment Center

www.diagnoseq.com.tr info@diagnoseq.com.tr

DiagnoSeq



# Only 1 in ~300,000 donors meet her needs<sup>1</sup>

She needs a new kidney, but with high anti-HLA antibodies and a cPRA of 99.999% she would need ~300,000 match runs to give a 95% probability of finding an acceptably matched donor.<sup>1,2</sup>

You're committed to making the transplant happen, we're committed to helping you have the option.



Please **visit booth #4** for more information

1. Keith DS, et al. Clin J Am Soc Nephrol. 2016;11(4):684-693.

2. Kuppachi S, Axelrod DA. Transpl Int. 2020;33(3):251-259.

This photo has been reproduced with patient approval.

© 2024 Hansa Biopharma.Hansa Biopharma and the beacon logo are registered trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved. www.hansabiopharma.com HANSA-PR.GL0.24.001-001 | April 2024

## KÎ NANOTYPE<sup>™</sup> KÎ HOLOGRAFT<sup>™</sup>

# NANOTYPE DEMOAT BOOTH #9

CHECK THE DEMO SCHEDULE AT THE OMIXON BOOTH

## OMIXON SYMPOSIUM MAY 21, 2024, 17:30 | HALL A



Big step towards diagnostics with Nanopore Sequencing





Donor-derived cfDNA as diagnostic tool in kidney transplantation

## Karin Boer, PhD Erasmus MC Transplant Institute niversity Medical Center Rotterdar

University Medical Center Rotterdam Rotterdam, the Netherlands



A NANOT

"\$0r

Introduction of NanoTYPE in the HLA typing routine activity of a French Histocompatibility and Immunogenetics Laboratory

## Romain FERRU-CLEMENT, PhD

Histocompatibility and Immunogenetics Laboratory French Blood Centre, Site of Poitiers



37<sup>™</sup> EFI Conference **May 20-23, 2024** 

## WE LIVE TO EXCITE



# ENJOY THE SYMPHONY OF ANTIBODY DIAGNOSTICS


Be a maestro as you orchestrate your antibody identification, using HISTO SPOT® HLA AB. From diluted serum to results generation, all steps are performed in a **fully automated** instrument; always finely tuned. No need for extra calibration protocols, **saving time, money** and **reagents.** HISTO MATCH software delivers **simple analysis** and **highly specific results** in a virtuoso performance.

HISTO SPOT® HLA AB

- HIGHLY REPRODUCIBLE
- FLEXIBLE THROUGHPUT (1-96 SAMPLES)
- OPTIMIZED SAMPLE BUFFER REDUCES UNSPECIFIC REACTIONS TO A MINIMUM
- CLASS I AND CLASS II ALL CLINICALLY RELEVANT SEROLOGICAL SPECIFICITIES COVERED



FIND OUT MORE NOW



## 38<sup>th</sup> European Immunogenetics & Histocompatibility Conference

**14–17 May 2025, Prague, Czech Republic** Prague Congress Centre



www.efi-conference.org



EFI 2025 Conference, Prague, Czech Republic 38th European Immunogenetics & Histocompatibility Conference